Next Article in Journal
Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin®) in Ischemic Stroke
Next Article in Special Issue
Recent Advances in Porphyrin-Based Inorganic Nanoparticles for Cancer Treatment
Previous Article in Journal
Estradiol-Induced Epigenetically Mediated Mechanisms and Regulation of Gene Expression
Previous Article in Special Issue
Photoacoustic Imaging Probes Based on Tetrapyrroles and Related Compounds
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 9
10.3390/ijms21093178
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Novel Phenothiazine-Bridged Porphyrin-(Hetero)aryl dyads: Synthesis, Optical Properties, In Vitro Cytotoxicity and Staining of Human Ovarian Tumor Cell Lines

by
Eva Molnar
1,
Emese Gal
1,
Luiza Gaina
1,
Castelia Cristea
1,*,
Eva Fischer-Fodor
2,3,
Maria Perde-Schrepler
2,
Patriciu Achimas-Cadariu
4,5,
Monica Focsan
6 and
Luminita Silaghi-Dumitrescu
1
1
The Research Center on Fundamental and Applied Heterochemistry, Department of Chemistry, Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, 11 Arany Janos street, RO-400028 Cluj-Napoca, Romania
2
Department of Radiobiology and Tumor Biology, Institute of Oncology “Prof.Dr. Ion Chiricuta”, 34-36 Republicii street, RO-400015 Cluj-Napoca, Romania
3
Medfuture Research Center for Advanced Medicine, University of Medicine and Pharmacy Iuliu Hatieganu, 8 Babes street, RO-400012 Cluj-Napoca, Romania
4
Department of Surgery, Institute of Oncology “Prof.Dr. Ion Chiricuta”, 34-36 Republicii street, 400015 Cluj-Napoca, Romania
5
Department of Surgery and Gynecological Oncology, University of Medicine and Pharmacy Iuliu Hatieganu, 23 Marinescu street, 400337 Cluj-Napoca, Romania
6
Institute for Interdisciplinary Experimental Research in Bionanoscience, Nanobiophotonics Laboratory, Babeş-Bolyai University, 42 Laurian street, 400271 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(9), 3178; https://doi.org/10.3390/ijms21093178
Submission received: 26 March 2020 / Revised: 24 April 2020 / Accepted: 26 April 2020 / Published: 30 April 2020
(This article belongs to the Special Issue Advances in the Chemistry of Porphyrins and Related Macrocycles)
Browse Figures
Review Reports Versions Notes

Abstract

:
We report here the synthetic procedure applied for the preparation of new AB3-type and trans-A2B2 type meso-halogenophenothiazinyl-phenyl-porphyrin derivatives, their metal core complexation and their peripheral modification using Suzuki–Miyaura cross coupling reactions with various (hetero)aryl (phenothiazinyl, 7-formyl-phenothiazinyl, (9-carbazolyl)-phenyl and 4-formyl-phenyl, phenyl) boronic acid derivatives. The meso-phenothiazinyl-phenyl-porphyrin (MPP) dyes family was thus extended by a series of novel phenothiazine-bridged porphyrin-(hetero)aryl dyads characterized by UV–Vis absorption/emission properties typical to the porphyrin chromophore, slightly modulated by increasing the size of peripheral substituents. Three phenothiazine-bridged porphyrin-heteroaryl dyads with fluorescence emission above 655 nm were selected as fluorophores in red spectral region for applications in cellular staining of human ovarian tumors. In vitro experiments of cell metabolic activity displayed a moderate toxicity on human ovarian tumor cell lines (OVCAR-3, cisplatin-sensitive A2780 and cisplatin-resistant A2780cis respectively). Visualization of the stained living cells was performed both by fluorescence microscopy imaging and by fluorescence lifetime imaging under two photon excitation (TPE-FLIM), confirming their cellular uptake and the capability of staining the cell nucleus.

Graphical Abstract

1. Introduction

The multiple functionalization possibilities of the highly stable planar macrocyclic porphin core combined with the huge progress recorded in the development of methodologies for synthetic organic chemistry mostly concurred with the expansion of recent literature data documenting new porphyrin derivatives with tailored chemical and optical properties. Introduction of appropriate donor/acceptor substituents and/or metal complexation contributed to the modification of structural factors, such as molecular symmetry, size and degree of conjugation of the π-electronic system, emphasizing a high impact on the optical performances of the porphyrin-based materials. Among the various heteroaromatic units attached to the porphine chromophore aiming the modulation of its photophysical properties, the introduction of an electron rich phenothiazine unit gave fruitful returns; e.g., fluorescent porphyrins emitting intense red light with high fluorescent quantum yields [1] “push−pull” porphyrin dyes for photon to energy conversion systems [2,3,4,5] as well as potential biologically active compounds [6]. The syntheses, optical properties and electrochemical behaviors of meso-phenothiazinyl-phenyl porphyrin (MPP) dyes were first reported by our group [7] followed by the description of their metal complexation [8].
The Suzuki–Miyaura cross-coupling between organoboron derivatives and organic halides in the presence of a palladium catalyst and a base became a powerful methodology for carbon–carbon bond formation [9]. This palladium-mediated cross-coupling reaction heavily benefits from the availability of: organoboron reagents (which are inert to water and oxygen, and characterized by thermal stability and low toxicity [10]); tetra-coordinated palladium-phosphine complex catalysts, such as Pd(PPh3)4, Pd(PPh3)2Cl2, Pd(dppf)Cl2 or Pd2(dba)3 [11]; and different bases, such as Cs2CO3 [12], K2CO3 [13], KOtBu [14], K3PO4 [15] or NEt3 [16].
A vast array of methodology options became accessible taking into consideration that both phenothiazine and porphyrin derivatives can be used as coupling partners in Suzuki–Miyaura cross coupling reactions either as halogeno or arylboronic derivatives. Phenothiazinylboronic acid derivatives were successfully synthesized from brominated phenothiazines either by bromine–lithium exchange followed by trapping with trialkylborate or by palladium-catalyzed borylation with tetramethyl dioxoborolane [17], while various (hetero)aryl substituents were attached to the phenothiazine core by Suzuki cross-coupling when starting with commercial chlorophenothiazine [18] or readily accessible 3,7-halogeno-phenothiazine derivatives [19,20,21]. The coupling of A2B2-type meso-bromoporphyrin with arylboronic acid derivatives was performed under mild conditions (aqueous Na2CO3 as a base in DMF) [22]. Starting from meso-borylporphyrin and meso-bromoporhyrin, [23] a meso-meso-linked porphyrin system was obtained using catalytic amounts of Pd(PPh3)4, Cs2CO3 in DMF/toluene solution. A combination of Cs2CO3 and a Pd(0)-complex was employed in the cross coupling of iodoferrocene and 5,15-diphenyl-10-borylporphyrin or other bulky boronic acids [24]. (e.g., polycyclic aromatic hydrocarbons [25].)
In this work, the MPP dyes family was expanded through the preparation of phenothiazine-bridged porphyrin-(hetero)aryl dyads. The described synthetic methodology is based on Suzuki–Miyaura cross coupling reaction between AB3 or trans-A2B2 type meso-bromophenothiazinyl-phenyl-porphyrines (generally labeled BrMPP) with (hetero)aryl boronic acid derivatives (phenothiazinyl, substituted phenyl). Novel A4-type phenyl-bridged porphyrin-phenothiazine dyads were obtained by Suzuki–Miyaura cross coupling between meso-tetrakis(4-bromo-phenyl)porphyrin (BrTPP) and phenothiazinyl-boronic acid derivatives. The optical UV–Vis absorption/emission properties of the newly synthesized compounds were investigated in our pursuit for π-expanded porphyrins characterized by a bathochromic shift of the typical absorption/emission maxima. The effect of metal core substitution on the UV–Vis optical response of AB3 or trans-A2B2 type halogenoMPP was also examined. Aiming the distinct visualization of human ovarian tumors, three phenothiazine-bridged porphyrin-heteroaryl dyads were tested as fluorophores in red spectral region for cellular staining of human ovarian tumors; following this goal their cytotoxicity was studied by means of colorimetric assays, while their ability to stain human ovarian tumor cell lines was proved by both fluorescence microscopy imaging and non-invasive two photon excited-fluorescence lifetime imaging microscopy (TPE-FLIM) technique.

2. Results

2.1. Synthesis of Novel MPP Dyes

2.1.1. Meso-(Halogenophenothiazinyl-Phenyl)Porphyrins

Meso-Halogenophenothiazinyl-phenylporphyrin dyes (halogen-MPP) of AB3-type (halogen-MPP 2 containing one peripheral halogenophenothiazine unit) and trans-A2B2 type (halogen-MPP 3 containing two peripheral halogenophenothiazine units) presented in Scheme 1 were prepared by mixed condensation of pyrrole with benzaldehyde and 7-bromo-10-methyl-phenothiazin-3-carbaldehyde 1a or 8-chloro-10-methyl-phenothiazin-3-carbaldehyde 1b respectively, based on our previously reported procedure, which affords MPP dyes containing a variable number of phenothiazinyl units attached to the peripheral meso positions of the central porphyrin core [7]. The presence of the halogen atom on the phenothiazine carbaldehyde substrate did not impede the outcomes of the macrocycle synthesis (yields 10–18%) and the separation of 2 and 3 obtained in 3:2 weight ratio was done by column chromatography. The starting bromophenothiazine carbaldehyde 1a was prepared from phenothiazine substrate by successive N-methylation; Vilsmeier formylation; and finally, bromination of the phenothiazine carbaldehyde intermediate [26], while 1b was prepared starting with commercial 2-chlorophenothiazine which required protection by N-methylation before applying the similar Vilsmeier formylation procedure.

2.1.2. Meso-(Halogenophenothiazinyl-Phenyl)Porphyrin Metal Complexes

Metalation of halogenoMPP AB3 type 2a,b and trans-A2B2 type 3a,b with d-block elements possessing polarizable valence electrons capable of perturbing the π-electron system of the porphyrin core was performed in order to underscore the effects of metal core substitution on their reactivities and UV–Vis optical properties. The complexation of the central cavity of the halogen-MPP macrocycles 2, 3 was accomplished by the treatment with the appropriate metal (II) acetate in N,N-dimethylformamide (DMF) solution [27]. In Scheme 2 are the metal-complexes obtained by incorporation of Zn(II), Pd(II) Ni(II) and Cu(II), metal ions respectively in halogen-MPP ligands containing one (4, 5) or two peripheral phenothiazine units (6, 7)

2.1.3. Phenothiazine-Bridged Porphyrin-(Hetero)Aryl Dyads

The presence of the halogen substituent on the phenothiazine unit in AB3 type porphyrin 2a offered the possibility for further extension of the aromatic π-electronic system by Suzuki–Miyaura cross coupling reaction with (hetero)aryl-(phenothiazinyl, 7-formyl-phenothiazinyl, 9-carbazolyl-phenyl, 4-formyl-phenyl or phenyl respectively) boronic acid derivatives, which generated the phenothiazine-bridged porphyrin-(hetero)aryl dyads 8–12, whereas trans-A2B2 type porphyrin 3a afforded the symmetric double phenothiazine-bridged porphyrin-(hetero)aryl dyads 13–15, as depicted in Scheme 3.
The cross coupling reaction was proven to be successfully performed when starting with BrMPP Zn(II) complex 4a and phenothiazinyl-boronic acid or phenyl-boronic acid derivative respectively, generating the phenothiazine-bridged porphyrin-phenothiazine/phenyl dyads Zn(II) complexes 8a and 11a.

2.1.4. Phenylene-Bridged Porphyrin-(Hetero)Aryl Dyads

Under similar Suzuki–Miyaura cross coupling reaction conditions, meso-tetrakis(4-bromo-phenyl)porphyrin 16 and formyl-phenothiazine boronic ester or phenyl boronic acids (9-carbazolylphenyl-, 4-formyl-phenyl) afforded the novel A4 type phenylene-bridged porphyrin-(hetero)aryl dyads 17–19 (Scheme 4) in good yields (~60%).
For each synthesized porphyrin, the structural assignments were based on the results of high-resolution mass spectrometry, 1H-NMR and 13C-NMR spectroscopy. The key signals generated by the porphyrin inner core protons were shifted upfield (δ = −2.7 ppm) in the free bases and disappeared from the 1H-NMR spectra of metal complexes 4–7. The symmetrical structure of each of the trans-A2B2 type derivatives 3 and 13–15 was unambiguously sustained by 1H-NMR spectra displaying four isochrone AB spin systems situated as low field signals (δ ≈ 8.9 ppm) for the eight protons situated in the beta positions of the pyrrole units encrypted in the macrocyclic structure (in Supplementary Materials are presented the NMR spectra of 3a (Figures S1 and S2), 5a (Figures S3 and S4) and 13 (Figures S5–S8) well as HRMS spectra of porphyrin ligand 3a (Figure S9) and metallo complexes with Zn(II) (Figure S10), Pd(II) (Figure S11) and Cu(II) (Figure S12 and S13).

2.2. Optical Properties of Novel MPP Dyes

2.2.1. UV–Vis Absorption Spectra

The UV–Vis linear absorption optical properties of the newly synthesized porphyrin derivatives recorded in dichloromethane (DCM) solution confirmed the presence of both phenothiazine and porphyrin chromophore systems. A UV absorption band situated in the range 240–260 nm typical to the phenothiazine chromophore is accompanied by a strong near-UV Soret band with maxima situated in the range 418–427 nm followed by four low intensity Q bands located in the visible spectral region in the range 515–520 nm, characteristic of the free-base etio-type porphyrin chromophore [7]. The positions of the absorption maxima for the synthesized porphyrin derivatives are depicted in Table 1. All the compounds are characterized by a dark purple color as a consequence of the intense absorption in the Soret band region. By examining the molar absorptivity values listed in Table 1, it can be seen that halogen-MPP 2a and A4 type meso-phenylene-bridged porphyrin-carbazole dyad 18 appear well fitted for dyes applications, while the presence of the phenothiazine bridge in porphyrin-(hetero)aryl dyads 8–15 does not promote a hyperchromic effect.
As can be seen in Figure 1 depicting the UV–Vis absorption spectra of phenothiazine-bridged porphyrin phenothiazine dyads, a hyperchromic effect was recorded in the case of AB3 type dyad 9 sensitive to the presence of auxochromic formyl group, whereas in the case of symmetric substitution in trans A2B2 type dyad 13, this hyperchromic effect appeared slightly diminished.
The characteristic UV–Vis absorption maxima recorded in solution for the prepared metal complexes of halogen-MPP are indicated in Table 2. As compared to the corresponding free base ligand, the electronic spectrum of each metal-complex displayed in the near UV range an intense Soret band without important shifting of its maxima position and in the visible region one or two Q bands, indicative of successful metal insertion in a square planar geometry [8].

2.2.2. UV–Vis Fluorescence Emission Spectra

Upon irradiation around the λmax corresponding to Soret band, in solution, phenothiazine-bridged porphyrin-(hetero)aryl dyads displayed fluorescence with noticeable Stokes shifts (above 8000 cm−1) and quantum yields between 0.08 and 0.19 when measured against TPP standard, as depicted in Table 3.
In Figure 2 are the emission spectra of phenothiazine-bridged porphyrin dyads containing phenothiazine 9 and 13 and carbazole 14 moieties, emphasizing the fluorophore properties of the symmetrical trans A2B2 type phenothiazine-bridged porphyrin-phenothiazine dyad 13.
The presence of the phenothiazine units in dye scaffolds may be considered as responsible on one hand for the energy dissipation by typical butterfly vibrations, thereby inducing low fluorescence emission in solution, but on the other hand, for enlarging the intermolecular distance due to its bent structure, thereby preventing the intermolecular π–π stacking and subsequently stimulating fluorescence in the aggregated state [28]. In solution, the parent MPP dyes displayed fluorescence emissions typical to the porphyrin core in 660–670 nm range [7], while the extension of the pending phenothiazine arms of A3B type and A2B2 type MPP with additional peripheral phenothiazine or phenyl units produced fluorescence quenching in compounds 8, and 11. The presence of formyl auxochromic groups in peripheral positions appeared beneficial by imparting molecular polarization via an electron withdrawing effect, and thus fluorescence emissions were recorded for compounds 9, 12, 13 and 15, as shown in Table 3. Phenothiazine-bridged porphyrin-carbazole dyads A3B type 10 and A2B2 type 14 displayed fluorescence emissions in similar range. The symmetrical A4 type phenylene-bridged porphyrin-(hetero)aryl dyads did not display fluorescence emission regardless the nature of the peripheral units: formyl-phenothiazine 17, N-phenyl carbazole 18 and phenyl-carbaldehyde 19.

2.3. Biological Activity Evaluation of Phenothiazine-Bridged Porphyrin-Phenothiazine Dyad Fluorescent Dyes 9, 13 and 15

Pursuing our goal of enabling the distinct visualization of human ovarian tumors, fluorescent dyes 9, 13 and 15 (Table 3) displaying fluorescence emission in solution above 650 nm and containing the carbaldehyde functional units susceptible to passing on the affinity towards the bio-materials were examined in vitro in terms of their cytotoxicity and their capacity for staining living cells by subcellular localization in human ovarian tumor A2780, cisplatin-resistant ovarian adenocarcinoma cells A2780cis and OVCAR-3 cell lines.

2.3.1. MTT Colorimetric Assay

The cells’ viability was tested using the MTT colorimetric assay (dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) following a previously reported colorimetric protocol [29]. Separate serial dilutions of each dye 9, 13 and 15 were employed in the treatment of ovarian adenocarcinoma cells lines under study. The modification in cell viability was observed by monitoring the concentration of the purple formazan formed after 24 h of incubation and reflected by the recorded optical density (OD) of the sample. The cells’ viability was expressed as percentage of survival in treated versus untreated (control) cell populations, and the results are shown in Table 4.
A close inspection of the data in Table 4 suggested that there were no significant differences between the cytotoxicity of the tested dyes 9, 13 and 15, each of them exhibiting a moderate toxicity on ovarian tumor cell lines in vitro (one-way analysis of variances, Bonferroni post-test, in the 95% confidence interval). From the viewpoint of the cell’s growth inhibition, A2780cis was the most resistant, while the folate receptor-rich OVCAR-3 cell line appeared the most susceptible to being affected.

2.3.2. Alamar Blue Assay

The metabolic activity of the ovarian adenocarcinoma cells lines under study was evaluated by the Alamar Blue fluorimetric test [30] in the presence of dyes 9, 13 and 15 using the same eight serial dilutions ranging from about 250 to 2 µM employed in the MTT colorimetric assay (Table 4). After 24 h of incubation, the nonfluorescent Alamar Blue dye was reduced by cell metabolic activity to the pink fluorescent resofurin dye (excitation at 570 mn, emission detected at 585 nm). In Figure 3, the correlation between fluorescence intensity and concentration for the tested fluorescent dyes against ovarian adenocarcinoma cells A2780 is shown. (In the Supplementary Material there is a similar correlation for ovarian adenocarcinoma A2780cis (Figure S14) and OVCAR3 cells (Figure S15).
The data provided by the fluorescence assessment were used to build a linear regression of dose–response relationship for each tested compound, and to quantify the results with the mathematic parameter hillslope, as presented in Table 5.
The deepest drops in metabolic rate, represented by negative hillslopes (Table 5) have been recorded for cisplatin-sensitive A2780 (−655.4) and cisplatin-resistant A2780cis (−567.1) cell lines subsequent to the treatment with 13, while for the folate-rich OVCAR-3 cell line, the largest metabolic rate reduction was caused by 9 (−344.8).

2.3.3. Cell Fluorescence Imaging

Fluorescence microscopy became an indispensable tool in single-molecule investigations, providing a high signal-to-noise ratio for visualization while still retaining the key features in the physiological context of native biological systems [31]. Fluorescent porphyrin derivatives characterized by large Stokes shift between absorption (~400 nm) and red/NIR emission were prospected in the fluorescence detection in various tissues or in vivo. In order to prevent the aggregation caused quenching effect due to π–π stacking aggregation favored by the planarity of the aromatic structure of the macrocycle, one chemical approach was to introduce various bulky groups as substituents of the porphyrin core [32]. Fluorescence imaging was carried out in order to investigate the internalization pathways of the selected fluorescent dyes 9, 13 and 15 inside the tested ovarian adenocarcinoma cells. The typical chemical reactivity of the carbaldehyde unit was the selected structural feature meant for passing on the affinity towards the bio-materials. In phenothiazine-bridged porphyrin-phenothiazine dyads A3B type 9 and A2B2 type 13 the formyl group was attached to the bent phenothiazine unit(s) prone to prevent the intermolecular π–π stacking, and green fluorescence was displayed by these staining agents in the aggregated state. Dye 15 containing the formyl group attached to peripheral flat phenylene units exhibited aggregation-caused fluorescence quenching, which limited its application.
The fluorescent dye concentration applied for cells staining was 50 µM estimated and was well fitted for both fluorescence visualization and avoidance of cytotoxicity effects responsible for reducing the cell viability. Figure 4 illustrates the A2780cis cells in a typical Bright-field image (Figure 4a); their corresponding fluorescence imaging after the standard nuclei staining with DAPI (4′,6-diamidino-2-phenylindole) (Figure 4b); and fluorescence imaging after staining with fluorescent dye 13 (Figure 4c).
The merged fluorescence image presented in Figure 4d reveals the green fluorescent signal of dye 13 overlain with the blue fluorescent signal of DAPI distributed inside the cells. This result allows us to conclude that fluorescent dye 13 is able to accumulate both in the perinuclear and the nuclei region of the ovarian adenocarcinoma cells, being susceptible to crossing the nucleus membrane.
In order to confirm the cellular uptake of dye 13, we further invoked two photon excited-fluorescence lifetime imaging (TPE-FLIM), an ideal non-invasive technique for live-cell imaging, which offers multiple advantages over linear optical microscopy, including acquisition of fluorescence image with deep light penetration generated by NIR excitation, less photodamage of living organism and negligible background signal [33]. In recent literature, functional porphyrins were specified as potential fluorescent probes for TPE fluorescence imaging of various tumoral cells. Thus, 2-acetyl-6-dimethyl-aminonaphthalene–porphyrin dyads, characterized by intramolecular fluorescence resonance energy transfer process (FRET) from the aminonaphthalene donor to the porphyrin acceptor unit, were employed for TPE fluorescence imaging of lung cancer A549 cells under the irradiation with a 740 nm femtosecond laser. [34,35] Mesoporous silica nanocomposites containing the photosensitizer 5,10,15,20-tetrakis-(1-methyl-4-pyridinio)porphyrin-tetra-(p-toluenesulfonate) were employed for targeted TPE-FLIM of human breast carcinoma cell line MCF-7 and the human lung cancer A549 cell line [36]. A non-covalent complex of lipid-coated semiconductor CdSe/ZnS quantum dots with a partially hydrogenated porphyrin (chlorin e6) photosensitizer was imaged within plasma membrane and intracellular compartments of living HeLa cells [37]. In our experiments, the chosen wavelength of the excitation laser was 800 nm, ensuring that the combined energy of two photons spanned the gap between the ground state and first excited electronic state of the fluorescent dye 13. Figure 5 illustrates the bright field image corresponding to A 2780 cells (Figure 5a) and the TPE-FLIM image where the contrast is based on the lifetime of the fluorophore 13 after staining A 2780 cells (Figure 5b).
The collected TPE-FLIM image presents the successful molecular binding of the dye 13 inside A2780 cells, giving the possibility of a distinct visualization of ovarian adenocarcinoma cells in NIR light.

3. Materials and Methods

3.1. Spectral Measurements

The mass spectra were recorded on a HRMS spectrometer LTQ Orbitrap XL-Thermo-Scientific (Waltham, MA USA) using APCI or ESI ionization technique. NMR spectra were recorded at room temperature on Bruker Avance instruments (Bruker BioSpin GmbH, Rheinstetten, Germany) (1H/13C: 400 MHz/100 MHz or 600 MHz/150 MHz) in solution (deuterated solvents chloroform (CDCl3) or DMSO). UV–Vis spectra were recorded in CH2Cl2 with a Perkin Elmer Lambda 35 spectrophotometer (Waltham (HQ), MA, USA). Fluorescence spectra in solution were recorded in DCM with a Perkin Elmer PL 55 spectrophotometer (Waltham (HQ), MA, USA). The fluorescence quantum yield was calculated using tetraphenylporphyrin (TPP) standard Φ = 0.13% in DCM solution [38].

3.2. Reagents

Phenothiazine, 2-chlorophenothiazine and phenylboronic acid were purchased from Sigma Aldrich; 10-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenothiazine-3-carbaldehyde was prepared according to the procedure described in the literature [39].
(4-(9H-carbazol-9-yl)phenyl)boronic acid was prepared according to the procedure described in the literature [40].
5,10,15,20-tetrakis(4-bromophenyl)-21H,23H-porphine was prepared according to the procedure described in the literature [41].
8-Cloro-3-formyl-10-methyl-phenothiazine 1b
To a cooled solution (0 °C) containing DMF (10 mL) and POCl3 (12 mL), 2-chloro-10-methyl-10H-phenothiazine (30 g, 0.12 mol) dissolved in 1,2-dichloroethane (150 mL) was added, and the reaction mixture was heated at 85 °C for 6 h. The reaction mixture was poured into cold water (200 mL) and extracted with ethyl-acetate (2 × 200 mL). The extract was dried over anhydrous magnesium sulfate and the solvent was removed till dryness. The product was purified by column chromatography, using a silica gel solid support and toluene as eluent. Yellow powder, yield 48% (16.1g), 1H-NMR (400 MHz, CDCl3) δppm 3.44 (s, 3H, CH3), 6.81(d, 1H, 4J = 1.9 Hz), 6.88 (dd, 1H, 3J = 6.4 Hz, 4J = 1.9 Hz), 6.97 (d 1H, 3J = 6.4 Hz), 7.03 (d, 1H, 3J = 6.8 Hz), 7.60 (d, 1H, 4J = 1.8 Hz), 7.68 (dd, 1H, 3J = 6.8 Hz 4J = 1.8 Hz), 9.81 (s, 1H, CHO); 13C-NMR (100 MHz, CDCl3) δppm 35.9 (N-CH3), 114.1, 115.2, 121.0 (Cq), 123.4 (Cq), 123.8, 127.8, 127.9, 130.6, 131.5 (Cq), 133.7 (Cq), 145.3 (Cq), 150.3 (Cq), 190.0 (CHO).

3.2.1. General Procedure for the Synthesis of AB3 and A2B2-Type Meso-Halogenophenothiazinyl-Porphyrins (2 and 3)

Propionic acid (100 mL) and acetic anhydride (3 mL) were stirred and heated at 110 °C for 1 h. After cooling at room temperature, benzaldehyde (12mmol), 10-methyl-10H-phenothiazinyl-carbaldehyde derivative (12mmol) and pyrrole (24 mmol) were added and the mixture was heated at 110 °C for 4 h. After completion, the obtained purple crystals were collected by filtration and washed with methanol to remove the traces of propionic acid. In the case in which the product did not precipitate, the solvent was removed by reduced pressure distillation and the residue was washed with methanol. The separation by column chromatography on silica gel gave the corresponding meso-halogenophenothiazinyl-porphyrins (2) and (3) respectively.
5,10,15-triphenyl-20-(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 2a
Starting with bromo-phenothiazine carbaldehyde 1a (4 g, 0.012 mol), benzaldehyde (1.3 mL, 0.012 mol), pyrrole (1.7 mL, 0.024 mol), propionic acid (100 mL) and acetic anhydride (3 mL) were added, and after purification by column chromatography using dichloromethane/petrol ether (2:1) as eluent, a purple powder was obtained; yield 18% (0.9 g). 1H-NMR (400 MHz, CDCl3) δppm -2.73 (s, 2H, NH), 3.60 (s, 3H), 6.85 (d, 1H, J = 7.4 Hz), 7.15 (d, 1H, J = 7.4 Hz), 7.37–7.40 (m, 2H), 7.78–7.83 (m, 9H), 8.01–8.05 (m, 2H), 8.25 (d, 6H, J = 7.2 Hz), 8.86–8.89 (m, 6H), 8.92 (d, 2H, J = 4.5 Hz); 13C-NMR (100 MHz, CDCl3) ppm 35.6, 112.5, 115.0, 115.4, 118.7 (Cq), 120.2 (4Cq), 121.2 (Cq), 125.5 (Cq), 126.7 (9C), 127.7 (6C), 129.7, 130.3 (2Cq), 132.9, 134.0, 134.5 (8C), 136.8 (Cq), 142.1 (8Cq), 145.0 (3Cq). HRMS-APCI calcd. for: C51H35BrN5S [M+H]+ 828.1717; found: 828.1791.
5,10,15-triphenyl-20-(2-chloro-10-methyl-10H-phenothiazin-7-yl)-21,23H-porphyrin 2b
Starting with phenothiazine carbaldehyde 1b (4 g, 0.012 mol), benzaldehyde (1.3 mL, 0.012 mol), pyrrole (1.7 mL, 0.024 mol), propionic acid (100 mL) and acetic anhydride (3 mL), a mixture of 2b and 3b was obtained. After separation by column chromatography using chloroform/heptane (2:1) as eluent, 2b was obtained as a purple powder; yield 14% (0.4 g); 1H-NMR (600 MHz, CDCl3) δppm −2.76 (s, 2H, NH), 3.66 (s, 3H), 7.01(s, 1H), 7.04 (d, 1H, J = 7.9 Hz), 7.18 (d, 1H, J = 8.1 Hz), 7.21 (d, 1H, J = 7.9 Hz), 7.78–7.82 (m, 9H,), 8.02–8.06(m, 2H), 8.24 (d, 6H, J = 8.2 Hz), 8.87 (d, 6H, J = 4.2 Hz), 8.91 (d, 2H, J = 4.2 Hz); 13C-NMR (150 MHz, CDCl3) δ ppm 35.7, 112.6, 114.8, 118.7 (Cq), 120.21, 120.23 (Cq), 121.6 (Cq), 121.8 (Cq), 122.5, 126.7 (9C), 127.7 (6C), 127.9 (3Cq), 128.2 (Cq), 129.0 (Cq), 132.9, 133.7 (2Cq), 133.9, 134.5 (8C), 137.0 (2Cq), 142.1 (4Cq), 144.8 (2Cq), 147.0 (2Cq). HRMS-APCI calcd. for: C51H35ClN5S [M+H]+ 783.2223; found: 783.2206.
5,15-diphenyl-10,20-bis(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 3a
Purification by column chromatography using dichloromethane/petrol ether (2:1) as eluent gave a purple powder; yield 12% (0.8 g); 1H-NMR (400 MHz, CDCl3) δ ppm –2.75, (s, 2H, NH), 3.58 (s, 6H), 6.83 (d, 2H, J = 9.2 Hz), 7.14 (d, 2H, J = 8.4 Hz), 7.37–7.41 (m, 4H), 7.77–7.81 (m, 6H), 7.98–8.04 (m, 4H), 8.24 (d, 4H, J = 8.2 Hz), 8.87 (d, 4H, J = 4.2 Hz), 8.91 (d, 4H, J = 4.2 Hz); 13C-NMR (100 MHz, CDCl3) δppm 36.0 (2C), 112.5 (2C), 115.0 (2C), 115.4 (2C), 118.8 (2Cq), 120.2 (2Cq), 121.1 (Cq), 125.3 (Cq), 125.5 (2Cq), 126.7 (4C), 127.7 (2C), 128.2 (2Cq), 129.0 (2C), 129.7 (4C), 130.3 (4C), 132.9 (2C), 134.0 (2C), 134.5 (4C), 136.8 (4Cq), 142.1 (4Cq), 145.0 (4Cq), 145.1 (4Cq). HRMS-APCI calcd. for: C58H39Br2N6S2 [M+H]+ 1043.1018; found: 1043.0968.
5,15-diphenyl-10,20-bis (2-chloro-10-methyl-10H-phenothiazin-7-yl)-21,23H-porphyrin 3b
Purification by column chromatography using dichloromethane/petrol ether (2:1) as eluent gave a purple powder; yield 10% (0.3 g); 1H-NMR (400 MHz, CDCl3) δ ppm-2.77 (s, 2H, NH), 3.65 (s, 6H), 7.03–7.05 (m, 4H), 7.16–7.21 (m, 4H), 7.76–7.81 (m, 6H), 8.02 (d, 4H, J = 7.4Hz), 8.23 (d, 4H, J = 8.4Hz), 8.86–8.90 (m, 8H); 13C-NMR (100 MHz, CDCl3) δ ppm 35.7 (2C), 112.6 (2C), 114.8 (4C), 118.8 (2Cq), 120.2 (2Cq), 121.6 (Cq), 121.7 (2Cq), 122.5 (4C), 126.7 (6C), 127.7 (4Cq), 127.9 (4C), 128.2 (Cq) 132.9 (2Cq), 133.7 (3Cq), 133.9 (3Cq), 134.5 (4C), 136.9 (4C), 142.0 (2Cq), 144.8 (2Cq), 147.0 (4Cq). HRMS-APCI calcd. for: C58H39Cl2N6S2 [M+H]+ 952.1976; found: 952.1905.

3.2.2. General Procedure for the Preparation of Metallo-Phenothiazinyl-Porphyrins

A solution of phenothiazinyl-porphyrin free base (2) or (3) (1 mmol) and Metal(II)-acetate (1.1 mmol) in DMF (50 mL) was heated to reflux for 6 h. The purification was achieved by column chromatography on silica gel, using chloroform/hexane (1:2) as eluent.
5,10,15-triphenyl-20-(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Zn-porphyrin 4a
Purple powder; yield 90% (0.9 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.59 (s, 3H), 6.83 (d, 1H, J = 8.7 Hz), 7.15 (d, 1H, J = 8.1 Hz), 7.32 (s, 1H), 7.38 (d, 1H, J = 8.7 Hz), 7.76–7.82 (m, 9H), 7.97 (s, 1H), 8.02 (d, 1H, J = 8.1 Hz), 8.26 (d, 6H, J = 8.4 Hz), 8.97–9.01 (m, 6H), 9.01 (d, 2H, J = 4.6 Hz); 13C-NMR (150 MHz, CDCl3) δ ppm 35.7, 112.3, 114.9 (Cq), 115.4, 119.7 (Cq), 120.9 (Cq), 121.2 (2Cq), 125.5 (Cq), 126.5 (6C), 126.6 (2C), 127.5 (3C), 129.6, 130.2, 131.8 (2Cq), 132.0 (6C), 132.1 (2C), 132.8, 133.8, 134.43 (2C), 134.45 (2C), 137.4 (Cq), 142.8 (4Cq), 144.8 (Cq), 145.0 (Cq), 150.2 (6Cq). HRMS-APCI calcd. for: C51H33BrN5ZnS [M+H]+ 892.0905; found: 892.0872.
5,10,15-triphenyl-20-(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Pd-porphyrin 4b
Purple powder; yield 80% (0.9 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.60 (s, 3H), 6.85 (d, 1H, J = 8.4 Hz), 7.15 (d, 1H, J = 8.5 Hz), 7.38 (s, 1H, H6), 7.40 (d, 1H, J = 8.4 Hz), 7.74–7.81 (m, 9H), 7.95–7.98 (m, 2H), 8.17–8.21(m, 6H), 8.81–8.85 (m, 6H), 8.89 (d, 2H, J = 4.8 Hz); 13C-NMR (150 MHz, CDCl3) δ ppm 35.7, 112.3 (Cq), 112.4, 114.3 (Cq), 115.0 (Cq), 115.4, 120.3 (Cq), 121.2 (Cq), 121.7 (2Cq), 125.5 (Cq), 126.71 (4C), 126.78 (2C), 127.4 (Cq), 127.7 (3C), 128.2 (Cq), 129.6, 130.3, 130.8 (2Cq), 130.9 (2C), 131.01 (6C), 131.04 (2C), 132.5, 133.4 (Cq), 133.5, 134.0 (2C), 134.1 (2C), 136.4 (Cq), 141.6 (4Cq), 141.7 (2Cq), 145.0 (Cq). HRMS-APCI calcd. for: C51H33BrN5PdS [M+H]+ 934.0648; found: 934.0641.
5,10,15-triphenyl-20-(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Ni-porphyrin 4c
Purple powder; yield 85% (0.9 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.57 (s, 3H), 6.82 (d, 1H, J = 8.2 Hz), 7.10 (d, 1H, J = 7.8 Hz), 7.37 (s, 1H), 7.38 (d, 1H, J = 8.2 Hz), 7.69–7.73 (m, 9H), 7.81 (d, 1H, J = 7.8 Hz), 7.82 (s, 1H), 8.02–8.05 (m, 6H), 8.76–8.78 (m, 6H), 8.80 (d, 2H, J = 4.8 Hz); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6 (CH3), 112.6 (CH), 115.0 (Cq), 115.4 (CH), 117.6 (Cq), 119.0 (2Cq), 121.3 (Cq), 125.5 (Cq), 126.9 (6CH), 127.7 (3CH), 129.6 (CH), 130.3 (CH), 132.0 (2CH), 132.1 (CH), 132.21 (4CH), 132.23 (2CH), 133.28 (CH), 133.7 (6CH), 135.5 (Cq), 140.8 (4Cq), 142.71 (6Cq), 142.74 (2Cq), 145.0 (Cq), 145.1 (Cq) HRMS-APCI calcd. for: C51H33BrN5NiS [M+H]+ 886.0967; found: 886.0952.
5,10,15-triphenyl-20-(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Cu-porphyrin 4d
Purple powder; yield 80% (0.86 g), HRMS-APCI calcd. for: C51H33BrN5CuS [M+H]+ 889.0930; found: 889.0912.
5,10,15-triphenyl-20-(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Zn-porphyrin 5a
Purple powder; yield 95% (1 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.62 (s, 3H), 6.97 (s, 1H), 7.00 (d, 1H, J = 8.4 Hz), 7.09 (d, 1H, J = 7.9 Hz), 7.16 (d, 1H, J = 8.4 Hz), 7.75–7.82 (m, 9H), 7.97 (s, 1H), 8.02 (d, 1H, J = 7.9 Hz), 8.23–8.25 (m, 6H), 8.96–8.98 (m, 6H), 9.00 (d, 2H, J = 4.6 Hz); 13C-NMR (150 MHz, CDCl3) δ ppm 35.7, 112.4, 114.7, 119.6 (Cq), 121.21 (2Cq), 121.27 (Cq), 121.3 (Cq), 121.7 (Cq), 122.4, 126.51 (4C), 126.57 (2C), 127.5 (3C), 127.8, 131.8 (3Cq), 132.01 (4C), 132.04 (2C), 132.8, 133.6 (Cq), 133.7, 134.41 (4C), 134.44 (4C), 137.6 (Cq), 142.8 (3Cq), 144.5 (Cq), 147.0 (Cq), 150.2 (5Cq). HRMS-APCI calcd. for: C51H33ClN5ZnS [M+H]+ 846.1431; found: 846.1419.
5,10,15-triphenyl-20-(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Pd-porphyrin 5b
Purple powder; yield 90% (1 g); 1H-NMR (400 MHz, CDCl3) δ ppm 3.64 (s, 3H, CH3), 7.02–7.08 (m, 2H, H1,9), 7.15 (d, 1H, 3J = 8.2 Hz, H3), 7.34 (d, 1H, J = 8.2 Hz H8), 7.73–7.79 (m, 9H, Hb,c), 7.95 (d, 1H, J = 8.2 Hz H4), 7.98 (s, 1H, H6), 8.17–8.20 (m, 6H, Ha), 8.82–8.84 (m, 6H, Hβ), 8.89 (d, 2H, 3J = 4.9 Hz, Hβ); 13C-NMR (100 MHz, CDCl3) δ ppm 35.6, 112.3, 114.3, 120.7 (Cq), 121.7 (2Cq), 121.9 (Cq), 122.8 (Cq), 123.3 (Cq), 126.7 (4C), 126.7 (2C), 127.4, 127.7, 127.7 (3C), 131.0 (4C), 131.0 (2C), 132.5, 133.3, 134.4 (4C), 134.4 (4C), 136.0 (Cq), 141.5 (4Cq), 141.6 (2Cq), 141.7 (2Cq), 141.7 (4Cq), 145.5 (Cq), 145.8 (Cq). HRMS-APCI calcd. for: C51H33ClN5PdS [M + H]+ 890.1178; found: 890.1147.
5,10,15-triphenyl-20-(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Ni-porphyrin 5c
Purple powder; yield 88% (0.94 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.58 (s, 3H), 6.96–7.02 (m, 2H), 7.11–7.13 (m, 2H), 7.68–7.73 (m, 9H), 7.81–7.83 (m, 2H), 8.03–8.07 (d, 6H), 8.78–8.81 (m, 8H); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6, 112.7, 114.7, 117.6 (Cq), 119.02 (Cq), 119.07, 121.7 (Cq), 121.8 (Cq), 122.5, 126.8 (6C), 127.7 (3C), 127.9, 132.0 (2C), 132.1, 132.24 (4C), 132.29 (2C), 133.1 (2Cq), 133.7 (6C), 135.7 (Cq), 140.9 (4Cq), 142.7 (8Cq), 144.9 (Cq), 146.9 (Cq). HRMS-APCI calcd. for: C51H33ClN5NiS [M+H]+ 840.1493; found: 840.1474.
5,10,15-triphenyl-20-(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Cu-porphyrin 5d
Purple powder; yield 80% (0.86 g); HRMS-APCI Calcd. for: C51H33ClN5CuS [M+H]+ 845.1435; found: 845.1420.
5,15-diphenyl-10,20-bis(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Zn-porphyrin 6a
Purple powder; yield 80% (0.85 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.52 (s, 6H), 6.78 (d, 2H, J = 8.5 Hz), 7.08 (d, 2H, J = 8.2 Hz), 7.26 (s, 2H), 7.34 (d, 2H, J = 8.5 Hz), 7.75–7.79 (m, 6H), 7.90–7.98 (m, 4H), 8.22–8.24 (m, 4H), 8.94–8.96 (m, 8H); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6 (2C), 112.2 (2C), 112.3 (Cq), 114.8 (2Cq), 114.9 (Cq), 115.4 (2C), 119.6 (Cq), 120.7 (Cq), 120.8 (Cq), 121.14 (Cq), 121.17 (2Cq), 125.3 (Cq), 125.4 (Cq), 126.53 (2C), 126.57 (2C), 127.4 (2C), 129.5 (2Cq), 129.6 (Cq), 130.2 (2C), 131.8 (2C), 132.03 (2C), 132.08 (2C), 132.8 (Cq), 132.9 (Cq), 133.82 (2Cq), 133.86 (Cq), 134.5 (2C), 137.5 (2C), 142.9 (2C), 144.7 (4Cq), 145.0 (2C), 150.2 (6Cq). HRMS-APCI calcd. for: C58H37Br2N6ZnS2 [M+H]+ 1105.0153; found: 1105.0118.
5,15-diphenyl-10,20-bis(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Pd-porphyrin 6b
Purple powder; yield 80% (0.88 g); 1H-NMR (400 MHz, CDCl3) δ ppm 3.54 (s, 6H), 6.81 (d, 2H, J = 8.8 Hz), 7.01 (d, 2H, J = 8.4 Hz), 7.20 (d, 2H, J = 8.8 Hz), 7.36 (s, 2H), 7.74–7.78 (m, 6H), 7.90–7.94 (m, 4H), 8.18 (d, 4H, J = 8.6 Hz), 8.81–8.87 (m, 8H); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6 (2C), 112.4 (2C), 114.4 (Cq), 115.0 (2Cq), 115.4 (2C), 120.4 (Cq), 121.9 (Cq), 125.3 (Cq), 125.50 (Cq), 125.54 (Cq), 1263.7 (6C), 127.8 (2C), 129.0 (2C), 129.7 (4C), 130.0 (2C), 130.0 (2C), 130.3 (2C), 131.0 (2C), 131.14 (2C), 131.19 (2C), 132.4 (2Cq), 133.5 (Cq), 134.11 (2Cq), 134.14 (2Cq), 136.3 (Cq), 141.61 (2Cq), 141.67 (2Cq), 141.7 (2Cq), 145.07 (2Cq), 145.09 (2Cq). HRMS-APCI calcd. for: C58H37Br2N6PdS2 [M+H]+ 1146.9871; found: 1146.9896.
5,15-diphenyl-10,20-bis(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Ni-porphyrin 6c
Purple powder; yield 85% (0.89 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.55 (s, 6H), 6.80 (d, 2H, J = 9.2 Hz), 7.08 (d, 2H, J = 8.0 Hz), 7.36–7.37 (m, 4H), 7.68–7.73 (m, 6H), 7.79–7.81 (m, 4H), 8.02 (d, 4H, J = 8.4 Hz), 8.76–8.80 (m, 8H); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6 (2C), 112.6 (2C), 115.0 (2Cq), 115.4 (2C), 117.7 (Cq), 119.1 (Cq), 121.4 (2Cq), 125.4 (2Cq), 126.9 (4C), 127.8 (2Cq), 129.6 (2C), 130.3 (2C), 132.0 (2C), 132.1 (4C), 132.2 (2C), 132.3 (2C), 133.2 (2C), 133.7 (6C), 135.5 (Cq), 140.8 (Cq), 142.70 (5Cq), 142.77 (5Cq), 145.0 (2Cq), 145.1 (2Cq). HRMS-APCI calcd. for: C58H37Br2N6NiS2 [M+H]+ 1099.0215; found: 1099.0195.
5,15-diphenyl-10,20-bis(7-bromo-10-methyl-10H-phenothiazin-3-yl)-21,23-Cu-porphyrin 6d
Purple powder; yield 80% (0.84 g); HRMS-APCI calcd. for: C58H37Br2N6CuS2 [M+H]+ 1104.0157; found: 1104.0133.
5,15-diphenyl-10,20-bis(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Zn-porphyrin 7a
Purple powder; yield 95% (1 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.59 (s, 6H), 6.95 (s, 2H), 6.99 (d, 2H, J = 8.4 Hz), 7.04 (d, 2H, J = 8.2 Hz), 7.14 (d, 2H, J = 8.4 Hz), 7.76–7.81 (m, 6H), 7.91 (d, 2H, J = 8.4 Hz), 7.99 (d, 2H, J = 8.2 Hz), 8.22–8.24 (m, 4H), 8.95–8.99 (m, 8H); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6 (2C), 112.4 (2Cq), 114.7 (4C), 119.74 (Cq), 119.78 (Cq), 121.23 (Cq), 121.28 (Cq), 121.53 (Cq), 121.59 (Cq), 122.4 (4C), 126.5 (4C), 127.5 (2C), 127.8 (2C), 131.8 (2C), 131.9 (2C), 132.0 (4C), 132.7 (Cq), 132.8 (Cq), 133.6 (2Cq), 133.7 (2Cq), 134.4 (2C), 137.5 (2Cq), 142.8 (2Cq), 144.4 (2Cq), 146.9 (2Cq), 150.23 (4Cq), 150.27 (4Cq) HRMS-APCI calcd. for: C58H37Cl2N6ZnS2 [M+H]+ 1017.1154; found: 1017.1118.
5,15-diphenyl-10,20-bis(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Pd-porphyrin 7b
Purple powder; yield 90% (1 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.65 (s, 6H), 7.00 (s, 2H), 7.04 (d, 2H, J = 8.4 Hz), 7.18–7.21 (m, 4H), 7.75–7.81 (m, 6H), 7.96–7.99 (m, 4H), 8.18 (d, 4H, J = 8.6 Hz), 8.82–8.90 (m, 8H); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6 (2C), 112.6 (2Cq), 114.7 (4C), 119.72, 119.77, 121.2 (2Cq), 121.50 (Cq), 121.53 (Cq), 122.5 (4C), 126.7 (4C), 127.5 (2C), 127.8 (2C), 131.8 (2C), 131.9 (2C), 132.0 (2C), 132.7 (Cq), 132.8 (Cq), 133.6 (2Cq), 133.7 (2Cq), 134.7 (4C), 137.5 (2Cq), 142.8 (2Cq), 144.4 (2Cq), 146.9 (2Cq), 150.2 (4Cq), 150.2 (4Cq). HRMS-APCI calcd. for: C58H37Cl2N6PdS2 [M+H]+ 1059.0931; found: 1059.0891.
5,15-diphenyl-10,20-bis(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Ni-porphyrin 7c
Ni-2j Purple powder; yield 85% (0.9 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.53 (s, 6H), 6.93 (s, 2H), 6.98 (d, 2H, J = 8.6 Hz), 7.05 (d, 2H, J = 8.2 Hz), 7.10 (d, 2H, J = 8.6 Hz), 7.68–7.72 (m, 6H), 7.78 (d, 2H, J = 8.2 Hz), 7.82 (s, 2H), 8.04 (d, 4H), 8.77–8.81 (m, 8H,); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6 (2C), 112.6 (2Cq), 114.7 (2C), 119.70, 119.75, 121.2 (2Cq), 121.50 (Cq), 121.53 (Cq), 122.7(4C), 126.8 (4C), 127.3 (2C), 127.9 (2C), 130.7 (2C), 131.4 (2C), 132.5 (2C), 132.9 (2Cq), 133.1 (2Cq), 133.5 (2Cq), 133.6 (2Cq), 134.7 (4C), 137.6 (2Cq), 142.9 (2Cq), 144.4 (2Cq), 146.9 (2Cq), 150.3 (4Cq), 150.4 (4Cq). HRMS-APCI calcd. for: C58H37Cl2N6NiS2 [M+H]+ 1009.1246; found: 1009.1214.
5,15-diphenyl-10,20-bis(8-chloro-10-methyl-10H-phenothiazin-3-yl)-21,23-Cu-porphyrin 7d
Purple powder; yield 80% (0.85 g); HRMS-APCI calcd. for: C58H37Cl2N6CuS2 [M+H]+ 1014.1188; found: 1014.1163.

3.2.3. General Procedure for the Synthesis of Suzuki Cross-Coupling Products

A degassed solution of halogenoMPP porphyrin 2a, 3a or 4a (0.12 mmol 1eq), aryl-boronic pinacolate ester (0.13 mmol, 1.1eq), Pd(PPh3)2Cl2 (0.006 mmol 0.05eq), K2CO3 (0.1 mmol) in DME (30 mL) and water (15), was heated to reflux under argon atmosphere for 18 h. After cooling to room temperature, the obtained precipitate was filtered off and washed with water. The purification of cross-coupling product was achieved by column chromatography on silica gel using DCM or chloroform as eluent.
5,10,15-triphenyl-20-[7-(10′-methyl-10′H-phenothiazine)-10-methyl-10H-phenothiazin-3-yl]-21,23H-porphyrin 8
By starting with 0.15 g 2a, purification of the reaction product by column chromatography using DCM eluent gave: purple powder; yield 50% (0.07 g); 1H-NMR (400 MHz, CDCl3) δ ppm -2.76 (s, 2H, NH), 3.64 (s, 6H), 6.87 (d, 1H, J = 8.3 Hz), 7.19 (d, 1H, J = 7.9 Hz), 7.39–7.42 (m, 3H), 7.69–7.80 (m, 12H), 7.89 (d, 1H, J = 8.2 Hz), 8.02 (s, 1H), 8.04 (d, 1H, J = 7.9 Hz), 8.12 (d, 1H, J = 7.6 Hz), 8.19 (d, 1H, J = 7.6 Hz), 8.21–8.25 (m, 6H), 8.86–8.88 (m, 6H), 8.91 (d, 2H, J = 4.7 Hz); 13C-NMR (100 MHz, CDCl3) δ ppm 35.3, 36.8, 112.2 (Cq), 113.7, 114.0, 114.2 (2C), 115.4 (Cq), 118.8 (Cq), 121.15 (Cq), 121.19 (2Cq), 122.5, 122.7, 123.0 (Cq), 123.8 (Cq), 124.9 (2C), 125.4 (2C), 126.4 (4C), 126.5, 127.2 (2C), 127.4 (2C), 127.5 (2C), 129.6 (Cq), 131.8 (Cq), 131.9 (6C), 132.8 (Cq), 134.41 (6C), 134.48 (3C), 137.6 (Cq), 140.5 (Cq), 142.9 (2Cq), 144.7 (4Cq), 145.1 (2Cq), 145.6 (2Cq), 148.6 (4Cq). HRMS-APCI calcd. for: C64H45N6S2 [M+H]+ 961.3068; found: 961.1229.
5,10,15-triphenyl-20-(7-(10′-methyl-10′H-phenothiazine)-10-methyl-10H-phenothiazin-3-yl)-21,23-Zn-porphyrin 8a
By starting with 0.15 g 4a, purification of the reaction product by column chromatography using DCM eluent gave: purple powder; yield 55% (0.09 g); 1H-NMR (400 MHz, CDCl3) δ ppm 3.39 (s, 3H), 3.60 (s, 3H), 6.81–6.86 (m, 3H), 6.93 (t, 1H, J = 7.4 Hz), 7.13 (s, 1H), 7.17–7.21 (m, 2H), 7.29 (d, 1H, J = 7.4 Hz), 7.31 (s, 1H), 7.34 (d, 1H, J = 7.6 Hz), 7.38 (d, 1H, J = 7.4 Hz), 7.76–7.80 (m, 9H), 7.98 (s, 1H), 8.01 (d, 1H, J = 7.8 Hz), 8.25 (d, 6H), 8.99 (d, 6H), 9.00 (d, 1H, J = 4.5 Hz), 9.03 (d, 1H, J = 4.5 Hz); 13C-NMR (100 MHz, CDCl3) δ ppm 35.3, 40.2, 112.2 (Cq), 114.0 (2C), 114.2 (2C), 115.4 (Cq), 118.8 (Cq), 121.11 (Cq), 121.14 (2Cq), 122.5 (2C), 123.0 (Cq), 123.8 (Cq), 124.9 (2C), 125.4 (2C), 126.4 (4C), 126.5, 127.2 (2C), 127.4 (2C), 127.5 (2C), 129.6 (Cq), 131.8 (Cq), 131.9 (6C), 132.8 (Cq), 134.4 (4C), 134.4 (3C), 137.6 (Cq), 142.9 (2Cq), 144.7 (Cq), 145.1 (Cq), 145.6 (2Cq), 150.2 (8Cq). HRMS-APCI calcd. for: C64H42N6S2Zn [M+H]+ 1022.2203; found: 1022.1968.
5,10,15-triphenyl-20-(7-(3′-formyl-10′-methyl-10H-phenothiazine)-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 9
When starting with 0.1 g 2a, purification of the reaction product by column chromatography with DCM gave a purple powder; yield 60% (0.07 g); 1H-NMR (600 MHz, CDCl3) δ ppm -2.76 (s, 2H, NH), 3.49 (s, 3H), 3.60 (s, 3H), 6.88–6.91 (m, 4H), 7.06–7.10 (m, 4H), 7.63–7.66 (m, 2H), 7.76–7.79 (m, 9H), 8.02–8.05 (m, 2H), 8.24 (d, 6H, J = 7.8 Hz), 8.87–8.93 (m, 8H), 9.83 (s, 1H, CHO); 13C-NMR (150 MHz, CDCl3) δ ppm 35.6, 35.8, 112.4, 113.6 (2C), 114.5, 115.0 (2C), 119.0 (2Cq), 120.2, 121.50 (Cq), 121.53 (Cq), 123.0, 123.6 (2Cq), 123.8 (2Cq), 125.0 (3C), 125.2 (2C), 125.7 (6C), 126.7 (4C), 127.7, 127.9, 130.5 (2C), 131.1 (2C), 133.0, (2Cq) 133.9 (2Cq), 134.2, 134.5 (4C), 135.5 (2Cq), 136.6, 142.1 (4Cq), 143.0 (2Cq), 145.0 (2Cq), 145.2 (3Cq), 150.7 (2Cq), 190.0 (CHO); HRMS (APCI) calcd. for: C65H45N6OS2 [M+H+] 989.3018; found: 989.3071.
5,10,15-triphenyl-20-[7-(4-(9H-carbazole-9-yl)phenyl)-10-methyl-10H-phenothiazin-3-yl]-21,23H-porphyrin 10
When starting with 0.15 g 2a, purification of the reaction product by column chromatography with chloroform/petrol ether 1:1 eluent gave: purple powder; yield 70% (0.12 g); 1H-NMR (400 MHz, CDCl3) δ ppm -2.75 (s, 2H, NH), 3.72 (s, 3H), 7.13 (d, 1H, J = 8.7 Hz), 7.21–7.23 (m, 1H), 7.31–7.35 (m, 3H), 7.44–7.47 (m, 3H, H), 7.51 (d, 2H, J = 8.1 Hz), 7.61 (m, 2H), 7.65 (d, 2H, J = 8.1 Hz), 7.72–7.80 (m, 9H), 8.03 (d, 1H, J = 8.0 Hz), 8.07 (s, 1H), 8.18 (d, 2H, J = 7.7 Hz), 8.24 (d, 6H, J = 7.5 Hz), 8.87 (s, 6H), 8.95 (d, 2H, 3J = 4.4 Hz); 13C-NMR (100 MHz, CDCl3) δ ppm 35.8, 109.8 (2C), 112.4 (2Cq), 114.7 (2Cq), 118.9 (2Cq), 119.9 (2C), 120.2, 121.5, 123.4 (2C), 125.9 (6C), 126.7 (9C), 127.4 (4C), 127.7 (2C), 127.9 (4C), 133.0 (2Cq), 134.0 (2Cq), 134.5 (8C), 135.0 (2Cq), 136.6 (2Cq), 136.7 (2Cq), 140.8 (4Cq), 142.1 (4Cq), 145.2 (Cq), 145.4 (2Cq); HRMS (APCI) calcd. for: C69H47N6S [M+H+] 991.3577; found: 991.3573.
5,10,15-triphenyl-20-(7-phenyl-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 11
By starting with 0.1 g 2a, purification of the reaction product by column chromatography using DCM eluent gave: purple powder; yield 60% (0.06 g); 1H-NMR (400 MHz, CDCl3) δ ppm -2.77 (s, 2H, NH), 3.65 (s, 3H), 7.04 (d, 1H, J = 8.5 Hz), 7.16 (d, 1H, J = 8.1 Hz), 7.30–7.33 (m, 1H, H), 7.42 (t, 2H, J = 7.4 Hz, J = 7.7 Hz), 7.50 (d, 2H, J = 7.6 Hz), 7.57 (d, 2H, J = 7.4 Hz), 7.72–7.75 (m, 9H), 7.99 (d, 1H, J = 8.1 Hz), 8.02 (s, 1H), 8.20 (d, 6H, J = 6.3 Hz), 8.83 (s, 6H), 8.90 (d, 2H, 3J = 4.5 Hz); 13C-NMR (100 MHz, CDCl3) δ ppm 35.9, 112.5, 114.8, 118.8 (Cq), 120.2 (2Cq), 121.4 (Cq), 124.1 (Cq), 126.0, 126.7 (6C), 126.9 (4C), 127.6, 127.7 (3C), 129.6 (Cq), 129.7 (7C), 130.3 (Cq), 130.3 (4C), 131.0 (Cq), 133.0, 133.7 (Cq), 134.0, 134.1 (Cq), 134.2 (Cq), 134.5 (4C), 134.9 (Cq), 136.9 (Cq), 142.1 (4Cq), 144.9 (Cq), 145.8 (Cq), 146.1 (Cq), 150.2 (Cq), 165.4 (Cq); HRMS (APCI) calcd. for: C57H40N5S [M+H+] 826.8334; found: 826.8308.
5,10,15-triphenyl-20-(7-phenyl-10-methyl-10H-phenothiazin-3-yl)-21,23-Zn-porphyrin 11a
By starting with 0.15g 4a, purification of the reaction product by column chromatography using DCM eluent gave a purple powder; yield 66% (0.1 g); 1H-NMR (600 MHz, CDCl3) δ ppm 3.37 (s, 3H), 6.87 (d, 1H, J = 8.7 Hz), 7.10 (d, 1H, J = 8.5 Hz), 7.21 (d, 1H, J = 8.1 Hz), 7.36–7.37 (m, 1H), 7.41 (d, 1H, J = 8.6 Hz), 7.46 (t, 1H, J = 7.3 Hz, J = 8.0 Hz), 7.51 (s, 1H), 7.55 (d, 1H, J = 6.4 Hz), 7.61 (d, 1H, J = 7.4 Hz), 7.76–7.80 (m, 9H), 8.03–8.04 (m, 2H), 8.24–8.25 (m, 6H), 8.97 (s, 6H, Hβ), 9.01 (d, 1H, J = 4.5 Hz), 9.04 (d, 1H, J = 4.5 Hz); 13C-NMR (150 MHz, CDCl3) δ ppm 37.6, 112.9, 115.8, 119.8 (Cq), 120.8 (2Cq), 121.4 (Cq), 123.7, 124.1 (Cq), 126.4 (6C), 126.6 (4C), 128.2, 128.7 (3C), 129.6 (Cq), 129.7 (7C), 130.5 (Cq), 131.9 (4C), 132.0, 133.7 (Cq), 133.8 (Cq), 134.0, 134.1 (Cq), 134.3 (Cq), 134.4 (4C), 137.3 (Cq), 139.2 (Cq), 142.8 (Cq), 145.5 (Cq), 146.4 (Cq), 148.8 (Cq), 150.2 (Cq), 150.4 (2Cq), 150.7 (Cq), 156.6 (Cq); HRMS (APCI) calcd. for: C57H38N5SZn [M+H+] 888.2134; found: 888.2108.
5,10,15-triphenyl-20-(7-(4-formyl-phenyl)-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 12
By starting with 0.15 g 2a, purification of the reaction product by column chromatography using DCM eluent gave: purple powder; yield 40% (0.04 g); 1H-NMR (600 MHz, CDCl3) δ ppm -2.74 (s, 2H, NH), 3.71 (s, 3H), 7.09 (d, 1H, J = 8.4 Hz), 7.22 (d, 1H, J = 7.8 Hz), 7.57–7.59 (m, 2H), 7.78–7.81 (m, 9H), 7.95 (d, 2H, J = 7.9 Hz), 8.04–8.06 (m, 2H), 8.19 (s, 1H), 8.24 (d, 6H, J = 6.4 Hz), 8.83 (d, 1H, J = 6.3 Hz), 8.87–8.93 (m, 8H), 10.06 (s, 1H, CHO); 13C-NMR (150 MHz, CDCl3) δ ppm 35.8, 112.5, 114.6, 118.8 (Cq), 120.2 (2Cq), 121.4 (Cq), 124.1 (Cq), 126.0, 126.7 (6C), 126.9 (4C), 127.7 (3C), 129.6 (Cq), 130.3 (Cq), 129.7 (7C), 130.3 (4C), 131.0 (Cq), 133.0, 133.7 (Cq), 134.0, 134.1 (Cq), 134.2 (Cq), 134.5 (4C), 134.9 (Cq), 136.9 (Cq), 142.1 (4Cq), 144.9 (Cq), 145.8 (Cq), 146.1 (Cq), 150.2 (Cq), 165.4 (2Cq), 191.8 (CHO); HRMS (APCI) calcd. for: C58H40N5OS [M+H+] 854.2948; found: 854.2949.
5,15-diphenyl-15,20-bis(7-(3′-formyl-10′-methyl-10′H-phenothiazin-7yl)-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 13
After starting with 0.1g 3a, purification of the reaction product by column chromatography with DCM gave 13 as a purple powder; yield 65% (0.1 g); 1H-NMR (400 MHz, CDCl3) δ ppm −2.75 (s, 2H, NH), 3.43 (s, 6H), 3.65 (s, 6H), 6.85 (s, 4H), 7.03 (d. 2H, J = 6.2 Hz), 7.18 (d, 2H, J = 8.0 Hz), 7.37–7.39 (m, 4H), 7.45 (s, 4H), 7.63–7.66 (m, 4H), 7.77–7.79 (m, 6H), 8.01 (d, 2H, 3J = 8.0 Hz), 8.04 (s, 2H), 8.23 (d, 4H, J = 6.2 Hz), 8.87–8.92 (m, 8H), 9.81 (s, 2H, CHO); 13C-NMR (100 MHz, CDCl3) δ ppm 35.7 (2C), 35.8 (2C), 112.4 (2Cq), 113.7 (4C), 114.6 (2Cq), 115.0 (4C), 119.0 (2Cq), 120.2 (2Cq), 121.5 (Cq), 123.0 (4C), 123.6 (2Cq), 123.9 (Cq), 125.1 (4C), 125.3 (2Cq), 125.7 (6C), 126.7 (4C), 127.7 (2C), 128.0 (2C), 130.5 (2Cq), 131.1 (4C), 133.0 (Cq), 134.0 (Cq), 134.3 (2Cq), 134.6 (4C), 135.5 (2C), 136.6 (2C), 142.1 (4Cq), 143.0 (4Cq), 145.0 (4Cq), 145.2 (2Cq), 150.8 (4Cq), 190.1 (2CHO); HRMS (APCI) calcd. for: C86H59N8O2S4 [M+H+] 1363.3638; found: 1363.3625.
5,15-diphenyl-15,20-bis [7-(4-(9H-carbazole-9-yl)phenyl)-10-methyl-10H-phenothiazin-3-yl)]-21,23H-porphyrin 14
By starting with 0.1 g 3a, purification of the reaction product by column chromatography with chloroform/petrol ether 1:1 eluent gave a purple powder; yield 70% (0.1 g); 1H-NMR (600 MHz, CDCl3) δ ppm -2.72 (s, 2H, NH), 3.72 (s, 6H), 7.12 (d, 2H, J = 9.0 Hz), 7.22 (d, 2H, J = 8.1 Hz), 7.33 (t, 4H, J = 7.4 Hz, J = 7.2 Hz), 7.46 (t, 4H, J = 7.9 Hz, J = 7.2 Hz), 7.50–7.52 (m, 4H), 7.61–7.62 (m, 2H), 7.62 (s, 2H), 7.66 (d, 4H, J = 8.3 Hz), 7.78–7.83 (m, 10H), 8.05 (s, 2H), 8.09 (s, 2H), 8.10 (d, 4H, J = 7.6 Hz), 8.25 (s, 4H), 8.88–8.96 (m, 8H); 13C-NMR (150 MHz, CDCl3) δ ppm 35.7 (2C), 109.8 (6C), 112.4 (2Cq), 114.7 (2C), 119.0 (Cq), 119.9 (2Cq), 120.0 (4C), 120.2 (2Cq), 120.3 (4C), 121.5 (Cq), 123.4 (6C), 124.0 (2Cq), 125.9 (2C), 125.9 (6C), 126.4 (2Cq), 126.7 (2C), 126.7 (2C), 127.4 (8C), 127.7 (2C), 127.7 (2C), 127.9 (8C), 133.0 (Cq), 133.0 (Cq), 134.0 (Cq), 134.0 (Cq), 134.6 (2Cq), 135.0 (Cq), 136.6 (2Cq), 136.7 (Cq), 139.0 (2Cq), 140.8 (8Cq), 142.1 (2Cq), 145.2 (2Cq), 145.4 (2Cq); HRMS (APCI) calcd. for: C94H63N8S2 [M+H+] 1368.4645; found: 1368.4595.
5,15-diphenyl-15,20-bis(7-(4-formyl-phenyl)-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 15
Purification by column chromatography with DCM gave: purple powder; yield 50% (0.06 g); 1H-NMR (600 MHz, CDCl3) δ ppm -2.76 (s, 2H, NH), 3.72 (s, 6H), 7.11 (d, 2H, J = 8.0 Hz), 7.23 (d, 2H, J = 7.1 Hz), 7.57 (s, 2H), 7.60 (d, 2H, J = 8.5 Hz), 7.77–7.81 (m, 10H), 7.96 (d, 4H, J = 8.0 Hz), 8.04–8.05 (m, 4H), 8.22–8.24 (m, 4H), 8.86–8.93 (m, 8H), 10.06 (s, 2H, CHO); 13C-NMR (150 MHz, CDCl3) δ ppm 35.8 (2C), 112.5 (2Cq), 112.6 (2Cq), 114.6 (2Cq), 118.8 (Cq), 120.3 (2Cq), 124.0 (Cq), 126.1 (2C), 126.7 (2C), 126.7 (2C), 126.9 (6C), 127.0 (2C), 127.2 (2Cq), 127.7 (2C), 130.4 (4C), 130.4 (2C), 133.0 (2C), 134.0 (2C), 134.2 (2C), 134.5(4C), 134.9 (4C), 136.8 (2C), 142.0 (2Cq), 144.9 (4Cq), 145.8 (4Cq), 146.2 (4Cq), 175.6 (4Cq), 191.8 (2CHO); HRMS (APCI) calcd. for: C72H49N6O2S2 [M+H+] 1093.3352; found: 1093.3356.
5,10,15,20-tetrakis-[4-(3-formyl-10-methyl-10Hphenothiazin-7-yl)phenyl]-21,23H-porphyrin 17
A mixture of 0.1 g BrTPP, 0.23 g 3-formyl-10-methyl-10Hphenothiazin-7-yl boronic pinacolate, 0.025 g Pd(PPh3)2Cl2, 0.12 g K2CO3, 30 mL DME and 15 mL H2O was refluxed for 18 h. Purification by column chromatography with DCM gave a purple powder; yield 64% (0.1 g); 1H-NMR (600 MHz, CDCl3) δ ppm –2.72 (s, 2H, NH), 3.58 (s, 12H), 6.97 (d, 4H, J = 8.2 Hz), 7.08 (d, 4H, J = 8.6 Hz), 7.18–7.20 (m, 4H), 7.72–7.77 (m, 12H), 7.95 (d, 8H, J = 7.9 Hz), 8.11–8.13 (m, 4H), 8.28–8.31 (m, 4H), 8.85–8.95 (m, 8H), 9.87 (s, 4H, CHO); HRMS (APCI) calcd. for: C100H67N8O4S4 [M+H+] 1572.4196; found: 1572.3790.
5,10,15,20-tetrakis-(4′-(9H-carbazole-9yl)-[1,1′-biphenyl]-4yl)-21,23H-porphyrin 18
A mixture of 0.1 g BrTPP, 0.17 g (4-(9H-carbazol-9-yl)phenyl)boronic acid, 0.025 g Pd(PPh3)2Cl2, 0.12 g K2CO3, 30 mL DME and 15 mL H2O was refluxed for 18 h. Purification by column chromatography with DCM gave a purple powder; yield 65% (0.1 g); 1H-NMR (600 MHz, CDCl3) δ ppm -2.70 (s, 2H, NH), 7.38 (t, 6H, J = 7.2 Hz, J = 7.4 Hz), 7.53 (t, 6H, J = 7.5 Hz, J = 7.5 Hz), 7.62 (d, 4H, J = 8.1 Hz), 7.83 (d, 8H, J = 7.8 Hz), 7.91–7.94 (m, 6H), 8.09–8.12 (m, 10H, H), 8.14 (d, 8H, J = 7.9 Hz), 8.24 (d, 8H, J = 7.8 Hz), 8.38 (d, 4H, J = 7.5 Hz), 8.87–8.91 (m, 8H), 9.03 (s, 4H); 13C-NMR (150 MHz, CDCl3) δ ppm 109.9 (8C), 120.1 (16Cq), 120.4 (8C), 123.5 (8C), 125.4 (4Cq), 126.0 (16C), 127.6 (8C), 128.7 (16C), 130.0 (8C), 135.2 (4Cq), 135.8 (4Cq), 135.8 (4Cq), 140.9 (12Cq); HRMS (APCI) calcd. for: C116H75N8 [M+H+] 1580.6142; found: 1580.6138.
5,10,15,20-tetrakis-(4′-formyl-[1,1′-biphenyl]-4yl)-21,23H-porphyrin 19
A mixture of 0.1 g BrTPP, 0.015 g 4-formylphenylboronic acid, 0.025 g Pd(PPh3)2Cl2, 0.12 g K2CO3, 30 mL DME and 15 mL H2O was refluxed for 18 h. Purification by column chromatography with DCM gave a purple powder; yield 48% (0.05 g); 1H-NMR (600 MHz, CDCl3) δ ppm 2.65 (s, 2H, NH), 8.09 (d, 8H, J = 7.6 Hz), 8.12–8.16 (m, 16H), 8.38 (d, 8H, J = 7.7 Hz), 8.98 (s, 8H), 10.19 (s, 4H, CHO); HRMS (APCI) calcd. for: C72H47N4O4 [M+H+] 1031.3591; found: 1031.3591.

3.3. In Vitro Biological Assay

The synthesized phenothiazine-bridged porphyrin-(hetero)aryl dyads with fluorescence properties selected for the biological assay which were simply labeled in this section as dyes were as follows:
5,10,15-triphenyl-20-(7-(3′-formyl-10′-methyl-10H-phenothiazine)-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 9
5,15-diphenyl-15,20-bis(7-(3′-formyl-10′-methyl-10′H-phenothiazin-7yl)-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 13
5,15-diphenyl-15,20-bis(7-(4-formyl-phenyl)-10-methyl-10H-phenothiazin-3-yl)-21,23H-porphyrin 15
The general equipment for the in vitro testing consisted of: a class II biological safety cabinet (from ESCO Micro Pte. Ltd., Singapore), an incubator with 37 °C and 5% CO2 parameters (Revco Ultima II, from Thermo Electron Corporation, Asheville, NC, USA), a centrifuge with swing-out rotors (32R from Hettich Lab Technology, Tuttlingen, Germany), an inverted phase microscope CKX41 (Olympus Life Sciences, Rockville, MD, USA) and a multiplate reader (Synergy2 from BioTek Company, Winooski, VT, USA).
The human ovarian tumor cell lines A2780 and A2780cis were acquired from the European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK) and the OVCAR-3 cell line was acquired from the American Type Culture Collection (ATCC, through LGC Standards GmbH, Wesel, Germany). All cell lines were grown in RPMI-1640 cell culture media. For A2780 and A2780cis cell lines the media was supplemented with 10% fetal bovine serum (FBS), while for OVCAR-3 cells 20% FBS was employed together with 0.01 mg/mL insulin from porcine pancreas (all media and supplements were from Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany).
For the cytotoxicity testing, the human ovarian tumor cell lines were harvested at subconfluency and plated on 96-well microplates at a concentration of 2.5 × 104 cells/well in 190 μL cell culture media, and after 24 h they were treated with the tested dyes 9, 13 and 15. Each dye was dissolved in dimethyl sulfoxide (provided by Merck, Darmstadt, Germany) and then eight serial solutions were prepared in phosphate buffered saline solution (PBS, from Sigma Aldrich). In each well, 10 µL of solution was distributed (8 serial concentrations for each dye) and the treated cells were incubated for 24 h. The final concentrations of the compounds in the cell media were in the range of 1.95–250.00 µM for 15, 1.88–240 µM for 9 and 1.64–210 µM for 13. On every plate, wells untreated with dyes were kept as references, and wells containing cell culture media with 9, 13 and 15 solutions (without cells) were kept as color controls for each concentration. Three independent tests were performed for each dye.
The microplates containing the treated human ovarian tumor cells were subjected to cytotoxicity testing using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide viability dye (MTT, from Sigma Aldrich), following a colorimetric protocol described before [29]. The optical densities of the sample supernatants, reflecting the cells’ viability, were recorded, and the survival rate was calculated relative to the untreated control cell populations.
The metabolic rate of the treated human ovarian tumor cells was evaluated by the Alamar Blue test (from Life Technologies Corporation, Eugene, OR USA), as described before [30]. Briefly: the cells were seeded on 96-well plates at the same density as for MTT testing, and incubated for 24 h with 8 different concentrations (from 1.95 to 250 µM) of tested dyes 9, 13 and 15, respectively, in triplicates. The data provided by the fluorescence assessment were used to build a linear regression of dose–response relationship for each tested compound, and to quantify the results with the mathematic parameter hillslope (GraphPad Prism Software La Jolla, CA, USA).
For the cellular uptake analysis by fluorescence microscopy, the human ovarian carcinoma cells were plated on 50mm µ-dish cell culture vessels (from Ibidi GmbH, Gräfelfing, Germany), at a concentration of 105 cells/mL in cell culture media, and the dishes were treated with 50 µM 9, 13 and 15 respectively and further kept for 24 h. Untreated cell culture vessels were kept as references. After the treatment, the cell culture media were removed, and the vessels were washed 3 times with PBS and fixed with a 4% paraformaldehyde (from Sigma Aldrich Chemie, Taufkirchen, Germany) solution in PBS. The µ-dishes were stained with 0.002 µg/mL 4′,6-diamidino-2-phenylindole solution in PBS (DAPI, from Serva Electrophoresis GmbH, Heidelberg, Germany), washed 2 times, and kept covered with PBS before the fluorescence microscope evaluation.

3.4. Fluorescence Imaging of Human Ovarian Tumor Cell Lines

The fluorescence images of A2780cis cells treated with 13 were collected with an inverted Axio Observer Z1 microscope (from Carl Zeiss), using a Compact Light Source HXP 120 C mercury lamp. Briefly, the light was reflected by a dichroic mirror using G 365 excitation filter (i.e., filter set 49 from Carl Zeiss) in order to visualize the cell nuclei, and an excitation filter BP 470/40 (i.e., filter set 38 from Carl Zeiss) was employed to image the localization of dye 13. The bright-field and fluorescence images were captured using a 63x iris oil immersion objective and a Zeiss AxioCam MRm monochrome microscope camera and then processed using the ZEN software.
Fluorescence lifetime imaging microscopy under two-photons excitation (TPE-FLIM) images on the A2780 cells post 24 h treatment were performed using a MicroTime 200 time-resolved confocal fluorescence microscope system (IX 71, Olympus) and coupled to a Mira 900 Titanium:Sapphire tunable femtosecond laser (from Coherent). The incubated A2780 cells were imaged under the microscope at 800 nm laser beam using up to 25 mW laser power, using the same system configuration described previously [42]. The signal was subsequently collected using a Plan N 40x objective with numerical aperture (NA) of 0.65 and spectrally filtered by a FF01-750 SP emission filter (Semrock, USA). The TPE-FLIM images were acquired and analyzed by the SymPhoTime software provided by PicoQuant. Bright-field images of the A2780 cells scanned through TPE-FLIM were collected on the same microscope, using an Olympus IX-2LW UCD condenser and an Olympus CAM-XC30 digital camera.

4. Conclusions

The family of meso-phenothiazinyl-phenyl-porphyrin MPP dyes was substantially extended by synthesizing the new halogen-MPP of AB3-type (containing one peripheral halogenophenothiazine unit) and the trans-A2B2 type (two peripheral halogenophenothiazine units) further employed, on the one hand, as ligands in new metal-complexes, and on the other hand, as scaffolds for peripheral modification by Suzuki–Miyaura cross coupling with various (hetero)arylboronic acid derivatives. The cross-coupling methodology applied afforded a series of meso-phenothiazine-bridged porphyrin-(hetero)aryl dyads in good yields (40–70%). The examination of the UV–Vis optical properties of the newly synthesized compounds emphasized the absorption/emission properties of the porphyrin chromophore slightly modulated by the substitution pattern. In comparison with para-phenylene, substitution of phenothiazine in positions 3,7 gave a less effective bridge for the extension of the π-electron system of the novel porphyrine-(hetero)aryl dyads. Increasing the size of the peripheral substituents did not improved the absorption characteristics of MPP dyes in the visible range, but it emphasized attractive NIR fluorophore properties for the symmetrical trans A2B2 type phenothiazine-bridged porphyrin-phenothiazine dyad 13.
According to cell viability colorimetric assays (MTT and Alamar Blue), the phenothiazine-bridged porphyrin-phenothiazine dyads 9, 13 and 15 exhibit a moderate cytotoxicity on ovarian tumor cell lines in vitro.
The green emissive dye 13 can be successfully employed for living human ovarian tumor cell staining, at 50 µM presenting a good cell internalization without affecting the cell viability and having the capability to stain the cells’ nuclei. Visualization of the stained cells can be performed both by fluorescence imaging and TPE-FLIM imaging.

Supplementary Materials

Supplementary materials can be found at https://www.mdpi.com/1422-0067/21/9/3178/s1.

Author Contributions

Conceptualization, E.G. and L.G.; methodology, L.G., E.G. and E.M.; validation L.G., E.G. and E.M.; formal analysis E.G. and E.M.; investigation, E.M.; resources, L.S.-D.; data curation, C.C.; writing—original draft preparation, C.C.; writing—review and editing, C.C.; visualization, L.G.; supervision, L.S.-D.; project administration, L.G.; funding acquisition; biological assay, M.P.-S. and E.F.-F.; biological activity study design, P.A.-C.; fluorescence imaging, M.F. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a grant of Romanian Ministry of Research and Innovation, CNCS - UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0142, within PNCDI III, and The APC was funded by PN-III-P4-ID-PCCF-2016-0142.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

MPPmeso-phenothiazinyl-phenyl porphyrin
BrMPPmeso-bromophenothiazinyl-phenyl porphyrin
BrTPPmeso-tetrakis(4-bromo-phenyl)porphyrin

References

  1. Qiu, X.; Lu, R.; Zhou, H.; Zhang, X.; Xu, T.; Liu, X.; Zhao, Y. Synthesis of phenothiazine-functionalized porphyrins with high fluorescent quantum yields. Tetrahedron Lett. 2008, 49, 7446–7449. [Google Scholar] [CrossRef]
  2. Prakash, K.; Alsaleh, A.Z.; Rathi, P.; Sharma, A.; Sankar, M.; D’Souza, F. Synthesis, Spectral, Electrochemical and Photovoltaic Studies of A3B Porphyrinic Dyes having Peripheral Donors. ChemPhysChem 2019, 20, 2627–2634. [Google Scholar] [CrossRef] [PubMed]
  3. Kumar, R.; Sudhakar, V.; Prakash, K.; Krishnamoorthy, K.; Sankar, M. Tuning the Photovoltaic Performance of DSSCs by Appending Various Donor Groups on trans-Dimesityl Porphyrin Backbone. ACS Appl. Energy Mater. 2018, 1, 2793–2801. [Google Scholar] [CrossRef]
  4. Zeng, K.; Tang, W.; Li, C.; Chen, Y.; Zhao, S.; Liu, Q.; Xie, Y. Systematic optimization of the substituents on the phenothiazine donor of doubly strapped porphyrin sensitizers: An efficiency over 11% unassisted by any cosensitizer or coadsorbent. J. Mater. Chem. A 2019, 7, 20854–20860. [Google Scholar] [CrossRef]
  5. Song, H.; Li, X.; Ågren, H.; Xie, Y. Branched and linear alkoxy chains-wrapped push-pull porphyrins for developing efficient dye-sensitized solar cells. Dyes Pigments 2017, 137, 421–429. [Google Scholar] [CrossRef]
  6. Abu-Melha, S. Efficient synthesis of meso-substituted porphyrins andmolecular docking as potential new antioxidant andcytotoxicity agents. Arch. Pharm. Chem. Life Sci. 2019, 352, e1800221. [Google Scholar] [CrossRef]
  7. Gal, E.; Brem, B.; Pereţeanu, I.; Gǎinǎ, L.; Lovasz, T.; Perde-Schrepler, M.; Silaghi-Dumitrescu, L.; Cristea, C.; Silaghi-Dumitrescu, L. Novel meso-phenothiazinylporphyrin dyes: Synthesis, optical, electrochemical properties and PDT assay. Dyes Pigments 2013, 99, 144–153. [Google Scholar] [CrossRef]
  8. Brem, B.; Gal, E.; Gaina, L.; Cristea, C.; Gabudean, A.M.; Astilean, S.; Silaghi-Dumitrescu, L. Metallo complexes of meso-phenothiazinylporphyrins: Synthesis, linear and nonlinear optical properties. Dyes Pigments 2015, 123, 386–395. [Google Scholar] [CrossRef]
  9. Miyaura, N.; Yamada, K.; Suzuki, A. A new stereospecific cross-coupling by the palladium catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynylhalides. Tetrahedron Lett. 1979, 20, 3437–3440. [Google Scholar] [CrossRef] [Green Version]
  10. Suzuki, A. Cross coupling reactions via organoboranes. J. Organomet. Chem. 2002, 653, 83–90. [Google Scholar] [CrossRef]
  11. Suzuki, A. Organoboranes in organic synthesis including Suzuki coupling reaction. Heterocycles 2010, 80, 15–43. [Google Scholar] [CrossRef] [Green Version]
  12. Kingston, J.V.; Verkade, J.G. Synthesis and Characterization of R2PN=P(iBuNCH2CH2)3N: A New Bulky Electron-Rich Phosphine for Efficient Pd-Assisted Suzuki−Miyaura Cross-Coupling Reactions. J. Org. Chem. 2007, 72, 2816–2822. [Google Scholar] [CrossRef]
  13. Dolliver, D.; Bhattarai, B.T.; Pandey, A.; Lanier, M.L.; Bordelon, A.S.; Adhikari, S.; Dinser, J.A.; Flowers, P.F.; Wills, V.S.; Schneider, C.L.; et al. Stereospecific Suzuki, Sonogashira, and Negishi Coupling Reactions of N-Alkoxyimidoyl Iodides and Bromides. J. Org. Chem. 2013, 78, 3676–3687. [Google Scholar] [CrossRef] [PubMed]
  14. Saito, B.; Fu, G.C. Alkyl–Alkyl Suzuki Cross-Couplings of Unactivated Secondary Alkyl Halides at Room Temperature. J. Am. Chem. Soc. 2007, 129, 9602–9603. [Google Scholar] [CrossRef] [PubMed]
  15. Baillie, C.; Zhang, L.; Xiao, J. Ferrocenyl Monophosphine Ligands: Synthesis and Applications in the Suzuki–Miyaura Coupling of Aryl Chlorides. J. Org. Chem. 2004, 69, 7779–7782. [Google Scholar] [CrossRef]
  16. Lipshutz, B.H.; Petersen, T.B.; Abela, A.R. Room-Temperature Suzuki–Miyaura Couplings in Water Facilitated by Nonionic Amphiphiles. Org. Lett. 2008, 10, 1333–1336. [Google Scholar] [CrossRef]
  17. Krämer, C.S.; Zimmermann, T.J.; Sailer, M.; Müller, T.J.J. Syntheses of Phenothiazinylboronic Acid Derivatives—Suitable Starting Points for the Construction of Redox Active Materials. Synthesis 2002, 9, 1163–1170. [Google Scholar] [CrossRef]
  18. Onoabedje, E.A.; Uchechukwu, C.O.; Knight, D.W.; Sarkar, A. Fuctionalization of Linear and Angular Phenothiazine and Phenoxazine Ring Systems via Pd(0)/XPhos Mediated Suzuki-Miyaura Cross-coupling Reactions. J. Heterocyclic Chem. 2016, 53, 1787–1794. [Google Scholar] [CrossRef]
  19. Grisorio, R.; Roose, B.; Colella, S.; Listorti, A.; Suranna, G.P.; Abate, A. Molecular Tailoring of Phenothiazine-Based Hole-Transporting Materials for High- Performing Perovskite Solar Cells. ACS Energy Lett. 2017, 2, 1029–1034. [Google Scholar] [CrossRef]
  20. Liu, X.; Tan, X.; Chen, Q.; Shan, H.; Liu, C.; Xu, J.; Chen, Z.K.; Huang, W.; Xu, Z.X. Facile synthesis of a dopant-free hole transporting material with a phenothiazine core for planar perovskite solar cells. RSC Adv. 2017, 7, 53604–53610. [Google Scholar] [CrossRef] [Green Version]
  21. Chao, P.; Gu, R.; Ma, X.; Wang, T.; Zhaod, Y. Thiophene-substituted phenothiazine-based photosensitisers for radical and cationic photopolymerization reactions under visible laser beams (405 and 455 nm). Polym. Chem. 2016, 7, 5147–5156. [Google Scholar] [CrossRef]
  22. Vaz, B.; Alvarez, R.; Nieto, M.; Paniello, A.I.; de Lera, A.R. Suzuki cross-coupling of meso-dibromoporphyrins for the synthesis of functionalized A2B2 porphyrins. Tetrahedron Lett. 2001, 42, 7409–7412. [Google Scholar] [CrossRef]
  23. Aratani, N.; Osuka, A. Synthesis of meso-meso Linked Hybrid Porphyrin Arrays by Pd-Catalyzed Cross-Coupling Reaction. Org. Lett. 2001, 3, 4213–4216. [Google Scholar] [CrossRef] [PubMed]
  24. Bakar, M.A.; Sergeeva, N.N.; Juillard, T.; Senge, M.O. Synthesis of Ferrocenyl Porphyrins via Suzuki Coupling and Their Photophysical Properties. Organometallics 2011, 30, 3225–3228. [Google Scholar] [CrossRef] [Green Version]
  25. Diev, V.V.; Schlenker, C.W.; Hanson, K.; Zhong, Q.; Zimmerman, J.D.; Forrest, S.R.; Thompson, M.E. Porphyrins Fused with Unactivated Polycyclic Aromatic Hydrocarbons. J. Org. Chem. 2012, 77, 143–159. [Google Scholar] [CrossRef] [PubMed]
  26. Kramer, C.S.; Zeitler, K.; Mu1ller, T.J.J. Synthesis of Functionalized Ethynylphenothiazine Fluorophores. Org. Lett. 2000, 2, 3723–3726. [Google Scholar] [CrossRef]
  27. Adler, A.D.; Longo, F.R.; Kampas, F.; Kim, J. On the preparation of metalloporphyrins. J. Inorg. Nucl. Chem. 1970, 32, 2443–2445. [Google Scholar] [CrossRef]
  28. Gong, J.; Han, J.; Liu, Q.; Ren, X.; Wei, P.; Yang, L.; Zhang, Y.; Liu, J.; Dong, Y.Q.; Wang, Y.; et al. An ideal platform of light-emitting materials from phenothiazine: Facile preparation, tunable red/NIR fluorescence, bent geometry-promoted AIE behaviour and selective lipid-droplet (LD) tracking ability. J. Mater. Chem. C 2019, 7, 4185–4190. [Google Scholar] [CrossRef]
  29. Boșca, B.A.; Ilea, A.; Sorițău, O.; Tatomir, C.; Miklášová, N.; Pârvu, A.E.; Mihu, C.M.; Melincovici, C.S.; Fischer-Fodor, E. Modulatory effect of curcumin analogs on the activation of metalloproteinases in human periodontal stem cells. Eur. J. Oral Sci. 2019, 127, 304–312. [Google Scholar] [CrossRef]
  30. Perde-Schrepler, M.; Florea, A.; Brie, I.; Virag, P.; Fischer-Fodor, E.; Vâlcan, A.; Gurzău, E.; Lisencu, C.; Maniu, A. Size-Dependent Cytotoxicity and Genotoxicity of Silver Nanoparticles in Cochlear Cells In Vitro. J. Nanomater. 2019, 2019, 6090259. [Google Scholar] [CrossRef] [Green Version]
  31. Shashkova, S.; Leake, M.C. Single-molecule fluorescence microscopy review: Shedding new light on old problems. Biosci. Rep. 2017, 37, 37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Yu, Q.; Chen, S.; Han, C.; Guo, H.; Yang, F. High solid fluorescence of novel tetraphenylethene-porphyrin. J. Lumin. 2020, 220, 117017. [Google Scholar] [CrossRef]
  33. Khadria, A.; Fleischhauer, J.; Boczarow, I.; Wilkinson, J.D.; Kohl, M.; Anderson, H.L. Porphyrin Dyes for Nonlinear Optical Imaging of Live Cells. iScience 2018, 4, 153–163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Zhu, M.; Su, C.; Xing, P.; Zhou, Y.; Gong, L.; Zhang, J.; Du, H.; Bian, Y.; Jiang, J. An AceDAN–porphyrin(Zn) dyad for fluorescence imaging and photodynamic therapy via two-photon excited FRET. Inorg. Chem. Front. 2018, 5, 3061–3066. [Google Scholar] [CrossRef]
  35. Zhu, M.; Zhang, J.; Zhou, Y.; Xing, P.; Gong, L.; Su, C.; Qi, D.; Du, H.; Bian, Y.; Jiang, J. Two-Photon Excited FRET Dyads for Lysosome-Targeted Imaging and Photodynamic Therapy. Inorg. Chem. 2018, 57, 11537–11542. [Google Scholar] [CrossRef]
  36. Lia, S.; Zhanga, Y.; Hea, X.-W.; Li, W.-Y.; Zhangab, Y.-K. Multifunctional mesoporous silica nanoplatform based on silicon nanoparticles for targeted two-photon-excited fluorescence imaging-guided chemo/photodynamic synergetic therapy in vitro. Talanta 2020, 209, 120552. [Google Scholar] [CrossRef]
  37. Valanciunaite, J.; Klymchenko, A.S.; Skripka, A.; Richert, L.; Steponkiene, S.; Streckyte, G.; Mély, Y.; Rotomskis, R. A non-covalent complex of quantum dots and chlorin e 6: Efficient energy transfer and remarkable stability in living cells revealed by FLIM. RSC Adv. 2014, 4, 52270–52278. [Google Scholar] [CrossRef] [Green Version]
  38. Prashanth, K.P.; Maiya, B.G. Aluminium(III) porphyrin based dimers and trimers: Synthesis, spectroscopy and photochemistry. New J. Chem. 2003, 27, 619–625. [Google Scholar] [CrossRef]
  39. Mao, M.; Zhang, X.; Cao, L.; Tong, Y.; Wu, G. Design of Bodipy based organic dyes for high-efficient dye-sensitized solar cells employing double electron acceptor. Dyes Pigments 2015, 117, 28–36. [Google Scholar] [CrossRef]
  40. Wang, P.; Fan, S.; Liang, J.; Ying, L.; You, J.; Wang, S.; Li, X. Carbazole-diphenylimidazole based bipolar material and its application in blue, green and red single layer OLEDs by solution processing. Dyes Pigments 2017, 142, 175–182. [Google Scholar] [CrossRef]
  41. Kurniawan, F.; Miura, Y.; Kartasasmita, R.E.; Mutalib, A.; Yoshioka, N.; Tjahjono, D.H. In Silico Study, Synthesis, and Cytotoxic Activities of Porphyrin Derivatives. Pharmaceuticals 2018, 11, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Suarasan, S.; Craciun, A.-M.; Licarete, E.; Focsan, M.; Magyari, K.; Astilean, S. Intracellular Dynamic Disentangling of Doxorubicin Release from Luminescent Nanogold Carriers by Fluorescence Lifetime Imaging Microscopy (FLIM) under Two-Photon Excitation. ACS Appl. Mater. Interfaces 2019, 11, 7812–7822. [Google Scholar] [CrossRef] [PubMed]
Ijms 21 03178 sch001 550
Scheme 1. Synthesis of novel halogen-MPP containing peripheral halogenophenothiazine units.
Scheme 1. Synthesis of novel halogen-MPP containing peripheral halogenophenothiazine units.
Ijms 21 03178 sch001
Ijms 21 03178 sch002 550
Scheme 2. Synthesis of Zn(II), Pd(II), Ni(II) or Cu(II) metal complexes of halogen-MPP.
Scheme 2. Synthesis of Zn(II), Pd(II), Ni(II) or Cu(II) metal complexes of halogen-MPP.
Ijms 21 03178 sch002
Ijms 21 03178 sch003 550
Scheme 3. Synthesis of phenothiazine-bridged porphyrin-(hetero)aryl dyads by Suzuki–Miyaura coupling between BrMPP and (hetero)arylboronic acid pinacolates.
Scheme 3. Synthesis of phenothiazine-bridged porphyrin-(hetero)aryl dyads by Suzuki–Miyaura coupling between BrMPP and (hetero)arylboronic acid pinacolates.
Ijms 21 03178 sch003
Ijms 21 03178 sch004 550
Scheme 4. Synthesis of A4 type meso-phenylene-bridged porphyrin-(hetero)aryl dyads.
Scheme 4. Synthesis of A4 type meso-phenylene-bridged porphyrin-(hetero)aryl dyads.
Ijms 21 03178 sch004
Ijms 21 03178 g001 550
Figure 1. UV–Vis absorption spectra of phenothiazine-bridged porphyrin-phenothiazine dyads in DCM solution.
Figure 1. UV–Vis absorption spectra of phenothiazine-bridged porphyrin-phenothiazine dyads in DCM solution.
Ijms 21 03178 g001
Ijms 21 03178 g002 550
Figure 2. Emission spectra of phenothiazine-bridged porphyrin dyads containing phenothiazine 9 and 13 and carbazole 14 moieties after excitation at 420 nm.
Figure 2. Emission spectra of phenothiazine-bridged porphyrin dyads containing phenothiazine 9 and 13 and carbazole 14 moieties after excitation at 420 nm.
Ijms 21 03178 g002
Ijms 21 03178 g003 550
Figure 3. Linear regression of the metabolic rate of ovarian cancer cell line A2780 versus the concentrations of the fluorescent dyes: (a) 9, (b) 13 and (c) 15.
Figure 3. Linear regression of the metabolic rate of ovarian cancer cell line A2780 versus the concentrations of the fluorescent dyes: (a) 9, (b) 13 and (c) 15.
Ijms 21 03178 g003
Ijms 21 03178 g004 550
Figure 4. Images of A2780cis cells: (a) Bright-field image (63x iris oil immersion objective). (b) Fluorescence images after staining with DAPI (G 365 excitation filter). (c) Fluorescence images after staining with 13 (excitation filter BP 470/40): (d) merged fluorescence images (b,c).
Figure 4. Images of A2780cis cells: (a) Bright-field image (63x iris oil immersion objective). (b) Fluorescence images after staining with DAPI (G 365 excitation filter). (c) Fluorescence images after staining with 13 (excitation filter BP 470/40): (d) merged fluorescence images (b,c).
Ijms 21 03178 g004
Ijms 21 03178 g005 550
Figure 5. Microscopy imaging of A 2780 cells: (a) Bright-field image (63xiris oil immersion objective). (b) TPE-FLIM image after incubation for 24 h with dye 13 (time-resolved confocal fluorescence microscope system coupled to a Ti:Sa tunable femtosecond laser at 800 nm, using up to 25 mW of the laser beam’s power).
Figure 5. Microscopy imaging of A 2780 cells: (a) Bright-field image (63xiris oil immersion objective). (b) TPE-FLIM image after incubation for 24 h with dye 13 (time-resolved confocal fluorescence microscope system coupled to a Ti:Sa tunable femtosecond laser at 800 nm, using up to 25 mW of the laser beam’s power).
Ijms 21 03178 g005
Table
Table 1. UV–Vis absorption maxima for halogen-MPP 2–3, meso-phenothiazine-bridged porphyrin-(hetero)aryl dyads AB3 type 8–12, trans A2B2 type 13–15 and meso-phenylene-bridged A4 type porphyrin-(hetero)aryl dyads 17–19 in DCM solution.
Table 1. UV–Vis absorption maxima for halogen-MPP 2–3, meso-phenothiazine-bridged porphyrin-(hetero)aryl dyads AB3 type 8–12, trans A2B2 type 13–15 and meso-phenylene-bridged A4 type porphyrin-(hetero)aryl dyads 17–19 in DCM solution.
Cpdλabs [nm]
PtzSoret ε [M−1 cm−1]Q4,3,2,1
2a259420 (369256)517, 554, 592, 652
2b259421 (186680)519, 555, 592, 651
3a259422 (134911)519, 555, 592, 651
3b257422 (193193)519,555, 598, 655
8259422 (61409)519, 555, 598, 655
8a260422 (58049)548, 585
9250420 (96961)515, 555, 590, 650
10250420 (79805)515, 554, 590, 650
11250418 (125483)514, 552, 590, 655
11a253422 (72411)548, 587
12245420 (191988)515, 555, 585, 645
13250420 (78229)520, 555, 590, 650
14245420 (182215)520, 555, 590, 650
15240420 (95928)520, 555, 590, 650
17-423 (174035)519, 548, 592, 652
18-420 (660743)515, 550, 590, 645
19-427 (78383)516, 555, 592, 642
Table
Table 2. UV–Vis linear optical properties of metal complexes of bromoMPP (4, 5) and chloroMPP (6,7) in DCM solution.
Table 2. UV–Vis linear optical properties of metal complexes of bromoMPP (4, 5) and chloroMPP (6,7) in DCM solution.
Cpd *Phenothiazine Porphyrin
λ [nm]λ [nm]λ [nm]
Soret ε [M−1 cm−1]Qalfa, beta
4a255425 (146756)550, 595
4b261418 (215712)524, 589
4c255425 (156953)555, 595
4d257416 (277707)538, 583
5a256422 (222108)539, 589
5b257418 (73993)524, 589
5c256416 (201024)538, 583
5d256416 (160106)539, 583
6a250425 (108260)555, 600
6b259422 (212575)526
6c260425 (235777)550, 595
6d259419 (207318)542, 587
7a257425 (193910)552, 593
7b256417 (208454)524
7c257418 (310212)531
7d257418 (219339)526
* Labeling of metal complexes: a Zn(II), b Pd(II), c Ni(II), d Cu(II).
Table
Table 3. Fluorescence emission spectral data of the synthesized phenothiazine-bridged porphyrin-(hetero)aryl dyads.
Table 3. Fluorescence emission spectral data of the synthesized phenothiazine-bridged porphyrin-(hetero)aryl dyads.
Compoundsλema [nm]Stokes Shift [cm−1]ϕFb
965585420.16
1065785880.14
1265485190.18
1365986350.19
1465284720.08
1565886120.15
a—excitation at λSoret, b—quantum yields against TPP standard.
Table
Table 4. Survival rate of ovarian adenocarcinoma cells treated with serial concentrations of 9, 13 and 15 respectively, versus the untreated reference cell population expressed as median values ± standard errors of means (SEM).
Table 4. Survival rate of ovarian adenocarcinoma cells treated with serial concentrations of 9, 13 and 15 respectively, versus the untreated reference cell population expressed as median values ± standard errors of means (SEM).
Compound9
Conc. [µM]240.00120.0060.0030.0015.007.503.751.88
% cell survival A278059.40 ± 2.4080.83 ± 3.2877.56 ± 3.5679.87 ± 4.6089.87 ± 3.7691.30 ± 3.4790.60 ± 4.3594.00 ± 4.51
A2780cis90.38 ± 2.7492.45 ± 2.5892.96 ± 1.45102.00 ± 1.5595.00 ± 3.1199.27 ± 2.3992.46 ± 3.7289.30 ± 1.20
OVCAR 356.94 ± 3.6169.58 ± 3.6883.68 ± 4.5076.36 ± 4.1783.02 ± 3.5882.89 ± 4.1880.82 ± 5.1287.81 ± 4.14
Compound13
Conc. [µM]210.00105.0052.5026.2513.136.563.281.64
% cell survival A278062.00 ± 0.9575.77 ± 1.0493.07 ± 3.1095.51 ± 2.3693.57 ± 2.92100.06 ± 1.6098.43 ± 3.36100.23 ± 0.39
A2780cis94.06 ± 3.7299.75 ± 1.4298.00 ± 2.30100.37 ± 4.1597.12 ± 3.4695.04 ± 3.39101.00 ± 1.73100.85 ± 2.54
OVCAR 344.14 ± 3.4666.89 ± 4.3573.07 ± 2.8075.21 ± 4.0982.19 ± 4.9182.65 ± 2.4585.37 ± 4.1889.92 ± 2.27
Compound15
Conc.[µM]250.00125.0062.5031.2515.637.813.911.95
% cell survival A278066.46 ± 1.7882.30 ± 3.6287.73 ± 1.7492.17 ± 0.6492.03 ± 1.1795.26 ± 5.1394.13 ± 3.2598.34 ± 2.11
A2780cis93.38 ± 3.1896.29 ± 1.4592.00 ± 1.15102.00 ± 2.8897.05 ± 1.1699 ± 2.3186.85 ± 1.1589 ± 2.52
OVCAR 344.51 ± 3.6764.41 ± 4.8480.26 ± 3.7583.20 ± 5.6579.65 ± 3.3885.89 ± 6.53101.45 ± 5.5994.11 ± 6.73
Table
Table 5. The capacities of 9, 13 and 15 compounds to reduce the metabolic potential of treated ovarian tumor cells in vitro, quantified through the mathematic parameter hillslope, derived from the linear regression of the dose–response relationship (concentration of compounds versus fluorescence intensity).
Table 5. The capacities of 9, 13 and 15 compounds to reduce the metabolic potential of treated ovarian tumor cells in vitro, quantified through the mathematic parameter hillslope, derived from the linear regression of the dose–response relationship (concentration of compounds versus fluorescence intensity).
CpdCell LinesLinear Regression Data
SlopeGoodness of Fit (R2)p ValueDeviation from Zero
9OVCAR-3−344.8 ± 30.660.83<0.0001Significant
A2780−646.9 ± 77.620.74<0.0001Significant
A2780cis−459.7 ± 42.010.86<0.0001Significant
13OVCAR-3−275.7 ± 32.170.75<0.0001Significant
A2780−655.4 ± 119.10.56<0.0001Significant
A2780cis−567.1 ± 58.130.82<0.0001Significant
15OVCAR-3−169.0 ± 23.170.68<0.0001Significant
A2780−460.7 ± 64.120.69<0.0001Significant
A2780cis−361.1 ± 53.160.71<0.0001Significant

Share and Cite

MDPI and ACS Style

Molnar, E.; Gal, E.; Gaina, L.; Cristea, C.; Fischer-Fodor, E.; Perde-Schrepler, M.; Achimas-Cadariu, P.; Focsan, M.; Silaghi-Dumitrescu, L. Novel Phenothiazine-Bridged Porphyrin-(Hetero)aryl dyads: Synthesis, Optical Properties, In Vitro Cytotoxicity and Staining of Human Ovarian Tumor Cell Lines. Int. J. Mol. Sci. 2020, 21, 3178. https://doi.org/10.3390/ijms21093178

AMA Style

Molnar E, Gal E, Gaina L, Cristea C, Fischer-Fodor E, Perde-Schrepler M, Achimas-Cadariu P, Focsan M, Silaghi-Dumitrescu L. Novel Phenothiazine-Bridged Porphyrin-(Hetero)aryl dyads: Synthesis, Optical Properties, In Vitro Cytotoxicity and Staining of Human Ovarian Tumor Cell Lines. International Journal of Molecular Sciences. 2020; 21(9):3178. https://doi.org/10.3390/ijms21093178

Chicago/Turabian Style

Molnar, Eva, Emese Gal, Luiza Gaina, Castelia Cristea, Eva Fischer-Fodor, Maria Perde-Schrepler, Patriciu Achimas-Cadariu, Monica Focsan, and Luminita Silaghi-Dumitrescu. 2020. "Novel Phenothiazine-Bridged Porphyrin-(Hetero)aryl dyads: Synthesis, Optical Properties, In Vitro Cytotoxicity and Staining of Human Ovarian Tumor Cell Lines" International Journal of Molecular Sciences 21, no. 9: 3178. https://doi.org/10.3390/ijms21093178

APA Style

Molnar, E., Gal, E., Gaina, L., Cristea, C., Fischer-Fodor, E., Perde-Schrepler, M., Achimas-Cadariu, P., Focsan, M., & Silaghi-Dumitrescu, L. (2020). Novel Phenothiazine-Bridged Porphyrin-(Hetero)aryl dyads: Synthesis, Optical Properties, In Vitro Cytotoxicity and Staining of Human Ovarian Tumor Cell Lines. International Journal of Molecular Sciences, 21(9), 3178. https://doi.org/10.3390/ijms21093178

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop